Terry Smith

As of 2026-07-03T14:41:08Z.

Core worldview

Terry Smith's investment philosophy is best understood as an accounting-quality worldview turned into a concentrated equity process. The slogan is short - "buy good companies, don't overpay, do nothing" - but the doctrine underneath is narrower and more demanding than generic quality investing. Fundsmith defines a good company as one that earns high returns on operating capital employed, turns reported profits into cash, has assets or franchises that are hard to replicate, can grow without excessive capital, and does not need leverage to make its economics work (Fundsmith Owner's Manual, 2025; Fundsmith Equity Fund prospectus, 2026).

This worldview came from Smith's first public identity as an accounting skeptic, not from a screen for fashionable growth stocks. His 1992 book Accounting for Growth was written after he questioned how apparently profitable UK companies could fail; Smith later said the book exposed accounting practices that flattered reported results, and biographical sources record that UBS Phillips & Drew dismissed him after publication (Fundsmith/FT article by Smith, 2015; FT Adviser, 2022; Pan Macmillan author bio). The later Fundsmith process is a more positive version of that same habit: do not ask first whether earnings are rising; ask whether the business actually earns cash on real capital and why competitors cannot copy it.

The philosophy is also an attack on much of the fund-management industry. Fundsmith argues that over-diversification, benchmark anxiety, excessive trading, sector rotation, and product proliferation make many active funds expensive index substitutes. The Owner's Manual explicitly says Fundsmith wants to diverge from benchmarks, avoid tracking-error thinking, keep dealing costs low, and concentrate in a limited number of businesses it can know well (Fundsmith Owner's Manual, 2025).

The edge: what markets misprice and why

Smith's claimed edge is that markets underappreciate the duration of exceptional economics when those economics are protected by intangible assets and customer habits. The Owner's Manual lists brands, distribution networks, installed bases, patents, market positions, and client relationships as examples of assets that do not show up cleanly on balance sheets yet can support high cash returns for long periods (Fundsmith Owner's Manual, 2025). The mispricing is partly accounting-based: reported earnings, adjusted EPS, and book-value measures often obscure the real franchise, while under-accounting for intangible assets can make durable compounders look optically expensive.

The second mispricing is behavioral. Smith believes investors pay too much attention to near-term market fashion, macro calls, and peer-relative risk, while underweighting the compounding effect of high incremental returns reinvested over many years. That is why the portfolio is designed to own companies that can reinvest at high rates, not merely companies that appear statistically cheap at a point in time (Fundsmith Owner's Manual, 2025; The Market/NZZ interview republished by Fundsmith, 2024).

The third mispricing is institutional. If other managers fear being different, they cluster near benchmarks and trade around earnings seasons; Smith tries to accept periods of visible underperformance in exchange for staying exposed to a small group of superior businesses. The 2024 and 2025 annual letters show this tension in real time: Fundsmith underperformed a market increasingly driven by a handful of AI and mega-cap index winners, while Smith argued that he would not own every Magnificent Seven stock at benchmark weight simply because an index did (Fundsmith 2024 annual letter, 2025; Fundsmith 2025 annual letter, 2026).

Process: idea sourcing -> research -> valuation & entry -> sizing -> portfolio construction -> sell discipline

Idea sourcing begins with the global universe of listed equities but quickly narrows to businesses with observable quality economics. The prospectus and factsheet describe the target as companies with high returns on capital, sustainable competitive advantages, low leverage needs, growth potential, resilience to change, and an attractive valuation (Fundsmith Equity Fund prospectus, 2026; Fundsmith Equity Fund June factsheet, 2026). The process screens out many sectors before stock-specific work starts: Smith has repeatedly rejected banks, most insurance, real estate, utilities, transport, and other businesses whose adequate returns depend on leverage, regulation, capital intensity, or commodity-like economics (Fundsmith bank-shares article, 2023; The Market/NZZ interview republished by Fundsmith, 2024).

Research then goes through the accounts. Smith's Tesco and AstraZeneca articles show the operating habit: look past rising EPS, adjusted earnings, and management definitions; follow return on capital, cash conversion, debt, leases, exceptional items, and whether accounting presentation is masking deteriorating economics (Tesco article by Smith, 2014; AstraZeneca article by Smith, 2017). Fundsmith's own short-form reports operationalize this by reporting portfolio-level return on capital employed, gross margin, operating margin, cash conversion, and interest cover (Fundsmith short-form report, 2024).

Valuation is not ignored, but it is subordinated to durability. Smith often argues that a low multiple can be a trap if the underlying business is weak, and a high multiple can be acceptable if the business compounds cash at high returns for long enough. In the 2024 annual letter, Fundsmith compared portfolio free-cash-flow yield with the S&P 500 median, illustrating that valuation work is cash-yield based rather than a simple P/E screen (Fundsmith 2024 annual letter, 2025). The 2022 report's discussion of Intuit's share-based compensation shows the same point: Smith adjusted reported cash flow for stock compensation and argued that the true free-cash-flow yield was materially lower than headline figures implied (Fundsmith short-form report, 2022).

Sizing and portfolio construction are deliberately concentrated. The main fund is normally expected to hold about 20-30 stocks, with no derivatives, no shorting, no currency hedging, no securities financing, and no other funds; the June 2026 factsheet showed 31 holdings, 7.0% cash, and 88% active share as of December 2024 (Fundsmith Equity Fund prospectus, 2026; Fundsmith Equity Fund June factsheet, 2026). UCITS rules still impose diversification arithmetic: a single issuer generally cannot exceed 10% and positions over 5% are constrained by the 40% basket limit, so the philosophy is concentrated but not unconstrained (Fundsmith Equity Fund prospectus, 2026).

The sell discipline is high-threshold rather than absent. Fundsmith's annual letters show low but non-zero turnover, including 3.2% in 2024 and 12.7% in 2025 (Fundsmith 2024 annual letter, 2025; Fundsmith 2025 annual letter, 2026). Sales are usually justified by changed business quality, management decisions, valuation, or a better opportunity. In 2025 Fundsmith sold Brown-Forman and PepsiCo because it saw structural pressure on alcohol and snacks from changing consumption patterns and weight-loss drugs; it also discussed the earlier sale and later repurchase of Intuit around the Mailchimp acquisition (Fundsmith 2025 annual letter, 2026).

Risk management

Smith's risk model starts with permanent impairment, not volatility. The first line of defense is business selection: avoid companies that need leverage, avoid fragile balance sheets, avoid sectors whose returns depend on credit expansion or commodity cycles, and avoid companies that cannot convert profits into cash (Fundsmith Owner's Manual, 2025; Fundsmith bank-shares article, 2023). This is why banks are a central negative example for him: even a good bank can require very high balance-sheet leverage to earn acceptable equity returns.

The second line of defense is simplicity. The main fund's prospectus rules out derivatives, currency hedging, securities financing transactions, total-return swaps, other collective funds, and strategic borrowing; temporary borrowing is a liquidity tool capped by scheme rules, not part of the return engine (Fundsmith Equity Fund prospectus, 2026). That leaves the portfolio exposed to equity drawdowns and currency moves, but Smith would rather accept transparent exposure than add instruments that create hidden risk or cost.

The third line is investor alignment and communication. The Owner's Manual tells investors in advance that the fund will miss fads and may underperform when markets chase fashionable themes; this is meant to reduce redemption-driven behavior that disrupts long-term ownership (Fundsmith Owner's Manual, 2025). The open-ended structure still creates daily-dealing liquidity obligations, so the prospectus also relies on listed large-company liquidity, stress testing, dilution tools, and in-specie redemption options for very large redemptions (Fundsmith Equity Fund prospectus, 2026).

Temperament & psychology

The required temperament is stubbornness under public measurement. Smith asks investors to tolerate looking wrong when expensive-looking compounders lag cyclicals, banks, commodities, or a narrow group of mega-cap winners. His letters are unusually combative for a long-only manager: they defend benchmark divergence, criticize passive-flow mechanics, criticize bank economics, and critique accounting presentation in named companies (Fundsmith Owner's Manual, 2025; Fundsmith 2025 annual letter, 2026; Fundsmith bank-shares article, 2023).

There is also an anti-theatrical side to the temperament: the desired portfolio action is mostly inaction. The discipline requires patience after purchase, but it also requires the humility to admit that a business once judged resilient may be changing. Independent critics have focused exactly there. Morningstar's 2024 downgrade said Fundsmith's stock-specific execution had mixed early sales such as Amazon and Adobe with late exits such as PayPal and Estee Lauder, while still retaining confidence in the broader process (Morningstar downgrade, 2024).

Evolution over career

Smith's philosophy evolved from forensic accounting toward positive compounding. In the early 1990s, the problem was detecting companies that looked profitable but were economically weak; Accounting for Growth catalogued accounting practices such as acquisition accounting, capitalized interest, leases, goodwill, pension surplus, and cash-flow presentation according to public book metadata (Internet Archive metadata; Google Books metadata). At Fundsmith, the same skepticism became an investable checklist: avoid accounting mirages and own the opposite - businesses whose cash economics are so clean and durable that low activity is rational.

The second evolution was from UK accounting critic to global quality-growth manager. Fundsmith launched in 2010 as a global equity fund rather than a UK special-situations vehicle; by 2026 the flagship factsheet showed a global portfolio with large exposures to consumer, healthcare, and technology franchises, and the US 13F captured a large but incomplete snapshot of Fundsmith LLP's reportable US holdings (Fundsmith Equity Fund June factsheet, 2026; Fundsmith LLP 13F, Q1 2026).

The third evolution is defensive: after 2021, Smith increasingly had to explain why the same process lagged. The 2022 annual letter emphasized rising interest rates and pressure on long-duration growth equities; the 2024 and 2025 letters emphasized AI, Nvidia, market-cap index concentration, passive flows, and US-dollar weakness (Fundsmith 2022 annual letter, 2023; Fundsmith 2024 annual letter, 2025; Fundsmith 2025 annual letter, 2026). This did not change the doctrine, but it sharpened its refusal to own every winner simply because it is big.

What he explicitly rejects

Smith explicitly rejects greater-fool investing, market timing, short-term trading, closet indexing, excessive diversification, derivatives, shorting, currency hedging, leverage as a return source, and businesses that require borrowed money to function (Fundsmith Owner's Manual, 2025; Fundsmith Equity Fund prospectus, 2026). He also rejects a fixation on reported EPS, because EPS can rise while return on capital and cash generation deteriorate; the Tesco and AstraZeneca pieces are case studies in that rejection (Tesco article by Smith, 2014; AstraZeneca article by Smith, 2017).

He is not rejecting technology or growth. He is rejecting businesses whose future cash economics cannot be predicted with enough confidence or whose valuation assumes returns on capital that may accrue to customers, suppliers, employees, or future competitors rather than current shareholders. His AI commentary in 2025 was framed this way: AI may be transformational, but that does not prove current AI infrastructure spending will earn adequate shareholder returns (Fundsmith 2025 annual letter, 2026).

Regimes where it thrives vs struggles

The philosophy should thrive when durable, asset-light, global businesses keep reinvesting at high incremental returns and markets are willing to value multi-year cash compounding. It is also well suited to periods when accounting quality, balance-sheet conservatism, and low turnover matter more than short-cycle exposure. The long-term record reported in Fundsmith's letters and factsheets is consistent with that claim, though the exact performance series belongs in the track-record task rather than this philosophy file (Fundsmith Equity Fund June factsheet, 2026; Fundsmith 2025 annual letter, 2026).

It struggles when market leadership is very narrow, benchmark weights become dominated by a few stocks the process will not own at full size, or the winners are capital-intensive technology suppliers whose returns are hard to underwrite. The 2024 semiannual letter said five stocks drove a large share of S&P 500 returns in the first half of 2024, and the 2025 letter framed passive index flows as reinforcing momentum in already-large companies (Fundsmith 2024 semiannual letter, 2024; Fundsmith 2025 annual letter, 2026). It can also struggle when rates rise sharply, because many high-quality compounders are long-duration equities whose valuation depends on cash flows far into the future; Smith's 2022 letter treated rising rates as an important pressure point (Fundsmith 2022 annual letter, 2023).

The philosophy is least transferable to vehicles where the same quality screen meets less favorable structure. Fundsmith Emerging Equities Trust was liquidated after poor performance, and the final report shows that emerging-market tax and settlement friction complicated the wind-down (Trustnet FEET article, 2022; FEET final report, 2025). Smithson, the small/mid-cap trust, faced a persistent discount and proposed restructuring into an OEIC after buybacks failed to solve the discount, illustrating that the investment philosophy does not eliminate vehicle and liquidity problems (Smithson 2025 report; Smithson restructuring RNS, 2025).

Tensions between stated philosophy and actual behavior

The first tension is sell discipline. "Do nothing" is powerful when it prevents frictional trading, but it can become a liability if evidence of business deterioration is slow to enter the decision. Morningstar's 2024 downgrade identified both early sales and late exits, and Trustnet reported that Smithson managers acknowledged turnover and transaction-cost concerns had contributed to keeping some holdings they probably should have sold (Morningstar downgrade, 2024; Trustnet Smithson interview, 2023).

The second tension is valuation. Smith says quality matters more than headline cheapness, but the process still needs a price discipline. The Nvidia and AI debate shows the hard edge of that judgment: avoiding an expensive, rapidly compounding leader may be philosophically consistent, yet it can create large opportunity cost when the market later validates the winner (Fundsmith 2024 annual letter, 2025; Morningstar 2026 review).

The third tension is scale and client behavior. Fundsmith tells investors not to chase fads or redeem at the wrong time, but the open-ended flagship still lives with public flows, daily dealing, and reputational pressure after multi-year underperformance. Trustnet reported large 2024 outflows from Fundsmith Equity even though the fund had positive absolute performance, showing that the client base may not always supply the temperament the strategy requires (Trustnet flows article, 2025).

The fourth tension is source framing. The cleanest evidence for Smith's philosophy is Smith and Fundsmith material, which is primary but also self-justifying. Independent sources generally do not reject the quality-compounding doctrine; their sharper critique is whether stock-level execution, vehicle design, and sell discipline have kept pace with the doctrine as assets, markets, and product structures changed (Morningstar downgrade, 2024; Morningstar 2026 review; AJ Bell Smithson analysis, 2025).

As of: 2026-07-03T16:33:10Z

Scope and evidence caveat

This file ranks Terry Smith's best public-equity trades primarily through Fundsmith Equity Fund, the flagship strategy launched in November 2010. It relies most heavily on Fundsmith's annual letters, short-form reports, factsheets, SEC 13F/13G filings, and selected independent coverage. Fundsmith does not publish a transaction-level ledger with cost basis, exact daily entry/exit prices, realized gains, or stock-level internal rates of return. The attribution figures below are Fundsmith/State Street annual contribution to fund performance, not audited trade P&L. SEC 13F filings are useful for U.S.-reportable quarter-end long holdings, but they are [single-source SEC snapshots] that exclude many non-U.S. ordinary shares and do not show cost, sale date, cash, intra-quarter trading, FX, short positions, or realized gains (SEC 13F FAQ, 2026).

Ranking method: repeated top-contributor appearances, duration, size, documented thesis, behavior under drawdown, and whether the result teaches something distinctive about Smith's process. Microsoft is the clearest best trade. Novo Nordisk and PayPal are deliberately treated as mixed cases: each generated material gains before becoming a test of sell discipline. Current independent check: Morningstar retained a Silver rating in June 2026 but still flagged one-, three-, and five-year underperformance, sell-discipline monitoring, key-person/internal-challenge risk, and stock-specific pain; these winners are process examples, not proof that the whole post-2021 Fundsmith record is unambiguously strong (Morningstar, 2026).

1. Microsoft - the best Fundsmith-era trade

Context and dates: Fundsmith began buying Microsoft in 2011, when Smith later said the position attracted unusually heavy criticism and the shares were roughly $25. By the 2025 annual letter, Microsoft had appeared ten times in Fundsmith's annual top-five contributors list, including 2023, 2024, and 2025. Fundsmith's 2025 short-form report also shows large Microsoft sale proceeds, so this is best described as a long-running holding with material trims rather than a fully exited trade (2023 letter, 2024 letter, 2025 letter, 2025 short-form report).

Thesis and how found: The Microsoft trade illustrates Smith's preferred pattern: a demonstrably high-return, cash-generative franchise became purchaseable because the market fixated on a temporary strategic and sentiment problem. The opened sources support the 2011 purchase timing, criticism, and later repeat contribution, but not a complete original investment memo; the operating thesis is reconstructed from Fundsmith's quality criteria and later Microsoft comments rather than from a disclosed stock-specific underwriting note. The cloud transition later amplified the outcome (2020 letter, Owner's Manual, 2025).

Size and structure: This was a long-only cash equity position in Fundsmith Equity Fund. The 2011 short-form report listed Microsoft at 5.17% of the portfolio at year-end. U.S. filings later show the reported U.S.-listed position's scale [single-source SEC 13F snapshots]: Fundsmith's 13F report showed Microsoft at about $434 million in Q1 2016 and about $4.37 billion in Q4 2021, before falling to about $770 million by Q1 2026 after trimming (2011 short-form report, Q1 2016 13F, Q4 2021 13F, Q1 2026 13F).

Entry, path, and drawdown: The path was not straight. Microsoft contributed strongly across multiple years, including +3.9 percentage points in 2021 and again in 2023, but was also a 2022 detractor during the rate-driven selloff in long-duration quality-growth equities. Smith did not treat that 2022 markdown as a thesis break (2021 letter, 2022 letter, 2023 letter).

Exit and P&L: Exact realized P&L is undisclosed. The best defensible evidence is cumulative annual attribution and the change in reported holding value. Named top-contributor years total roughly 23 percentage points of positive fund attribution [calculated from annual Fundsmith attribution tables; single-source] before offsetting detractor years and position-size changes. Fundsmith disclosed about GBP1.45 billion of Microsoft sale proceeds in 2025; in March 2026, Interactive Investor reported Smith confirmed the team had roughly halved Microsoft and Meta in 2025 because AI infrastructure spending might change the capital-light economics that made the companies fit Fundsmith's quality screen (2025 short-form report, Interactive Investor, 2026).

What it teaches: The trade is the canonical Fundsmith pattern: buy a high-quality compounding machine during a sentiment glitch, hold through noise, and let internal reinvestment do most of the work. It also shows that even the best winners eventually force a sell-discipline question when valuation and capital allocation change.

Sources: Fundsmith annual letters 2020-2025, 2011 short-form report, SEC 13F snapshots, 2025 short-form report, and Interactive Investor's 2026 trim report.

2. Meta Platforms - holding through the most criticized stock

Context and dates: Fundsmith bought Facebook/Meta by 2018. It was a detractor that year, then became a top contributor in 2019, 2020, 2023, 2024, and 2025. The 2025 letter says Meta had made its fifth appearance in the top-contributors list (2018 letter, 2019 letter, 2020 letter, 2025 letter).

Thesis and how found: The thesis rested on scale, habit formation, advertising targeting, margins, cash generation, and the option value of new products. Fundsmith has not disclosed a full stock-specific underwriting note, so the sourcing path is partly reconstructed from the annual-letter comments that Meta/Facebook was the most criticized holding and later a repeat contributor (2020 letter, 2023 letter).

Size and structure: This was a long-only public equity holding. Fundsmith's U.S. 13F position was about $2.29 billion at Q4 2021, about $2.79 billion at Q3 2024, and about $756 million at Q1 2026 after trims [single-source SEC 13F snapshots]. The 2025 short-form report lists Meta as the largest 2025 sale, with about GBP1.70 billion of proceeds (Q4 2021 13F, Q3 2024 13F, Q1 2026 13F, 2025 short-form report).

Entry, path, and drawdown: Meta was a -3.3 point detractor in 2022, a year when Fundsmith cited Meta's regulatory and competition problems and metaverse spending, before becoming a major contributor in the 2023-2024 rebound, when Meta contributed +4.5 and +4.1 percentage points respectively (2022 letter, 2023 letter, 2024 letter).

Exit and P&L: Exact trade P&L is undisclosed. Visible attribution is material: +2.0 points in 2019, +1.4 in 2020, +4.5 in 2023, +4.1 in 2024, and +1.1 in 2025 [calculated from annual Fundsmith attribution tables; single-source]. But the 2025 trims, disclosed and discussed publicly in 2026, mean the final economic result is still partly open.

What it teaches: Meta is a temperament trade. It required distinguishing reputational controversy and cyclical ad weakness from permanent impairment in the underlying advertising network. It also warns that the correct hold decision after a crash does not eliminate later questions about AI spending, valuation, or position size.

Sources: Fundsmith annual letters 2018-2025, SEC 13F snapshots, and the 2025 short-form report.

3. IDEXX Laboratories - the overlooked pet-health compounder

Context and dates: Fundsmith began buying IDEXX in 2015. It became a repeated contributor: +3.10 points in 2016, +1.0 in 2018, +3.1 in 2020, +1.9 in 2021, +1.4 in 2023, and +2.3 in 2025. The 2025 letter says IDEXX made its sixth appearance in the top-contributors list (2016 letter, 2018 letter, 2020 letter, 2025 letter).

Thesis and how found: IDEXX fit the Fundsmith template almost exactly: dominant niche position, consumables and recurring diagnostic revenue, high returns on capital, pricing power, and a secular pet-health tailwind. The specific sourcing path is not disclosed, but Smith identified IDEXX in 2016 as the world's largest maker of veterinary testing equipment after Fundsmith began buying in 2015 (2016 letter).

Size and structure: This was a long-only equity position. Fundsmith's Q1 2016 13F showed about $330 million of IDEXX. By Q4 2021, it was about $2.79 billion [single-source SEC 13F snapshots]. A 2023 Schedule 13G/A reported Fundsmith beneficially owned 4.448 million IDEXX shares, or 5.37%, while also checking Item 5 to report that it had ceased to be a greater-than-5% owner as of that filing date; use it as evidence of scale around year-end 2022, not proof of later ownership above 5% (Q1 2016 13F, Q4 2021 13F, IDEXX Schedule 13G).

Entry, path, and drawdown: IDEXX has also tested the patience rule. It was a 2024 detractor at -1.2 points as veterinary visits slowed after the Covid-era pet adoption surge. Smith explicitly framed the stock as a business he preferred to hold because selling might make it hard to rebuild the position before the recovery (2024 letter).

Exit and P&L: Exact P&L is undisclosed. The annual attribution evidence is strong, with roughly 12.8 positive points across named top-contributor years [calculated from annual Fundsmith attribution tables; single-source]. Fundsmith also disclosed IDEXX sale proceeds in 2023, but the subsequent 2025 top-contributor appearance indicates it remained an important holding after partial sales (2023 short-form report, 2025 letter).

What it teaches: IDEXX shows the value of finding a small but global monopoly-like niche where recurring revenue and reinvestment runway matter more than headline GDP. It also shows a limit: when Fundsmith owns a large percentage of a company, liquidity and the ability to rebuild a position become part of the hold decision.

Sources: Fundsmith annual letters 2016-2025, 2023 short-form report, SEC 13F snapshots, and IDEXX Schedule 13G/A.

4. Novo Nordisk - the GLP-1 winner that became a live risk case

Context and dates: Fundsmith began buying Novo Nordisk in 2016. The position became a top contributor in 2017, 2021, 2022, and 2023, when Fundsmith emphasized that Novo had been a successful investment before weight-loss drugs became the market's main story (2016 letter, 2017 letter, 2021 letter, 2023 letter).

Thesis and how found: The thesis combined a differentiated drug-discovery culture, foundation-controlled long-term orientation, leadership in diabetes care, and later the GLP-1 obesity market. Fundsmith's specific sourcing path is not disclosed, but the 2023 letter says the fund had owned Novo for seven years because of its unusual approach to drug discovery and foundation ownership, before the weight-loss-drug story dominated the market narrative (2023 letter).

Size and structure: This was a long-only equity position. Fundsmith does not disclose full Novo position size in the opened primary materials, and Novo sits mostly outside the U.S.-13F evidence set because it is a Danish issuer. The 2025 short-form report shows about GBP546 million of Novo Nordisk sale proceeds in the 2024 comparative period, evidence of material trimming [single-source Fundsmith short-form report] (2025 short-form report).

Entry, path, and drawdown: The positive years are clear: +1.5 points in 2017, +2.3 in 2021, +2.1 in 2022, and +3.6 in 2023. Then the trade turned. Novo was a -0.6 point detractor in 2024 and a -3.0 point detractor in 2025, as competition, illegal generic pressure in the U.S., and management execution damaged the story. The caveat remained live in 2025: Portfolio Adviser reported Novo Nordisk detracted -1.7 percentage points and Coloplast -0.5 points in the first half, while AJ Bell framed the Danish exposure as a risk case in patient quality-growth investing (2024 letter, 2025 letter, Portfolio Adviser, 2025, AJ Bell, 2025).

Exit and P&L: No total P&L is disclosed. The visible positive attribution through 2023 was large enough to qualify Novo as a major winner [calculated from annual Fundsmith attribution tables; single-source], but the 2024-2025 drawdown means the final ranking must carry a live caveat.

What it teaches: Novo is the best reminder that quality can decay through management execution and competitive pressure, not just through balance-sheet stress. The trade began as a Fundsmith archetype and became a test of whether patient ownership had turned into inertia.

Sources: Fundsmith annual letters 2016-2025, 2025 short-form report, Portfolio Adviser 2025, and AJ Bell 2025.

5. Stryker - an old friend in medical devices

Context and dates: Stryker has been in the portfolio since Fundsmith's early years. It was a detractor in 2011, then later a repeated top contributor, including 2013, 2014, 2016, and 2024. Smith said in the 2024 letter that Stryker was making its fifth top-contributor appearance (2011 letter, 2013 letter, 2014 letter, 2016 letter, 2024 letter).

Thesis and how found: Stryker was a classic high-return medical-device compounder: durable brand and sales-channel advantages, ongoing procedure volume, product innovation, and a long runway from aging populations and elective surgery demand. The specific sourcing path is not disclosed; the evidence opened here supports early ownership, repeated contribution, and Smith's later explanation that the 2024 contribution reflected recovery in elective-procedure backlogs.

Size and structure: This was a long-only cash equity holding. Stryker was 5.05% of the portfolio at the end of 2011. SEC filings showed about $387 million at Q1 2016, about $1.94 billion at Q4 2021, and about $1.01 billion at Q1 2026 [single-source SEC 13F snapshots] (2011 short-form report, Q1 2016 13F, Q4 2021 13F, Q1 2026 13F).

Entry, path, and drawdown: The main visible bumps were early underperformance and the Covid-era disruption in elective medical procedures. By 2024, the catch-up in elective surgery backlogs helped Stryker return to the top-contributor list with +1.3 points (2024 letter).

Exit and P&L: No realized P&L is disclosed, and Stryker remained a major position as of the latest 13F and factsheet evidence. Visible attribution is smaller than Microsoft or Meta, but the duration and repeat contribution make it one of the best process examples (Fundsmith factsheet).

What it teaches: Stryker is less dramatic than Microsoft, but perhaps closer to the pure Fundsmith ideal: an excellent company held for a very long time, with underperformance treated as noise when the business quality survived.

Sources: Fundsmith annual letters 2011-2024, 2011 short-form report, SEC 13F snapshots, and current Fundsmith factsheet.

6. Domino's Pizza - the early valuation-discipline winner

Context and dates: Domino's was one of the flagship fund's earliest winners. It appeared among top contributors in 2010 and 2011, was sold after a sharp rise in 2011, re-entered the portfolio later, contributed strongly again in 2013 and 2014, and was sold in 2015. Fundsmith described Domino's in 2015 as the best-performing share since inception (2010 letter, 2011 letter, 2013 letter, 2015 letter).

Thesis and how found: Domino's was a branded, capital-light consumer compounder with repeat purchase behavior, franchise economics, and strong unit growth. Fundsmith did not disclose the original sourcing path in the opened materials, but the 2011 letter makes clear the sell decision was valuation-driven rather than thesis-break-driven (2011 letter).

Size and structure: This was a long-only public equity trade. SEC 13F filings show a U.S.-reportable Domino's position of about $149 million at Q4 2013 and about $164 million at Q1 2014 [single-source SEC 13F snapshots]. The 2015 short-form report lists about GBP154.8 million of Domino's sale proceeds (Q4 2013 13F info table, 2015 short-form report).

Entry, path, and drawdown: The 2011 report says Domino's rose 113% before Fundsmith sold. After re-entry, Domino's contributed +3.02 points in 2013 and +2.0 points in 2014 (2013 letter, 2014 letter). This was not a seamless hold-forever story; it was a repeated buy-quality/sell-valuation trade.

Exit and P&L: Total P&L is undisclosed, but this is one of the few cases where the annual letter itself calls out best-performing status. The 2015 sale appears to have crystallized a substantial gain, although the exact cost basis is unavailable.

What it teaches: Domino's proves that Smith's three-part slogan is not mechanically buy-and-never-sell. Valuation can force action even in a high-quality business. It is also a useful counterexample to the later criticism that Fundsmith has sometimes sold too early or too late.

Sources: Fundsmith annual letters 2010-2015, Q4 2013 SEC 13F info table, and 2015 short-form report.

7. Philip Morris International - the controversial reduced-risk product compounder

Context and dates: Philip Morris has been a long-running Fundsmith holding. It was a positive contributor in 2011 and later appeared in the top contributors in 2019, 2022, 2024, and 2025. The 2025 letter says it made its fifth appearance in the list (2011 letter, 2019 letter, 2022 letter, 2024 letter, 2025 letter).

Thesis and how found: The thesis was not a generic tobacco yield trade. Fundsmith emphasized Philip Morris's reduced-risk products, especially heat-not-burn tobacco and nicotine pouches after the Swedish Match acquisition. The specific sourcing path is not disclosed; the evidence is Smith's repeated annual-letter commentary on reduced-risk products and repeat contribution (2024 letter, 2025 letter).

Size and structure: This was a long-only cash equity holding. U.S. filings show about $384 million at Q1 2016, about $1.94 billion at Q4 2021, and about $845 million at Q1 2026 [single-source SEC 13F snapshots]. The 2025 short-form report lists Philip Morris among the largest sales in both 2024 and 2025, but the current factsheet still shows it as a top holding (Q1 2016 13F, Q4 2021 13F, Q1 2026 13F, Fundsmith factsheet).

Entry, path, and drawdown: Philip Morris was a detractor in 2018 and 2020 before later contributions of +1.1 in 2022, +1.5 in 2024, and +1.5 in 2025. That pattern made it a hold-through-regulatory-and-sentiment trade rather than an unbroken winner (2018 letter, 2020 letter, 2025 letter).

Exit and P&L: Exact P&L is undisclosed. The strongest evidence is repeat top-contributor status, sizable 13F values, and disclosed partial-sale proceeds. ESG and public-health objections are real, so the trade should be assessed as an investment result, not as an ethical endorsement.

What it teaches: Philip Morris shows Smith's willingness to own a socially controversial business if he believes the economics and transition path are durable. It also shows how Fundsmith can make money where many quality-growth investors will not or cannot invest.

Sources: Fundsmith annual letters 2011-2025, SEC 13F snapshots, 2025 short-form report, and current Fundsmith factsheet.

8. PayPal - a winner that became a sell-discipline warning

Context and dates: PayPal entered Fundsmith's universe through the eBay separation and became a strong contributor in 2017, 2018, 2019, and especially 2020. It was later sold in 2022 after the thesis deteriorated. This makes it a greatest-trades candidate only with a caveat: the early trade worked, the late hold was more questionable (2017 letter, 2018 letter, 2019 letter, 2020 letter, 2022 letter).

Thesis and how found: The original thesis was a high-return digital-payments network with brand recognition, two-sided scale, and secular growth as commerce moved online. The specific sourcing path is not disclosed in the opened materials; the strongest direct evidence is PayPal's repeated annual top-contributor status before Smith's 2022 criticism of management execution and capital allocation.

Size and structure: This was a long-only public equity position. Fundsmith's Q4 2021 13F showed PayPal at about $2.46 billion before the collapse in fintech valuations [single-source SEC 13F snapshot]. The 2022 short-form report shows about GBP740 million of PayPal sale proceeds (Q4 2021 13F, 2022 short-form report).

Entry, path, and drawdown: The positive attribution was substantial, including +5.1 points in 2020 alone. But by 2021-2022, PayPal turned into a problem: Fundsmith's 2022 letter criticized customer engagement, cost control, and attention to overpriced acquisitions, and Morningstar later folded PayPal into its broader sell-discipline critique alongside Amazon, Adobe, and Estee Lauder (2022 letter, Morningstar downgrade, 2024, Guardian coverage, 2024).

Exit and P&L: Exact P&L is undisclosed. PayPal generated roughly 10.8 positive attribution points in its visible top-contributor years [calculated from annual Fundsmith attribution tables; single-source], then gave back some of the gain before Fundsmith exited in 2022. It belongs near the bottom of this list because the trade was profitable in phase one but less convincing as an end-to-end example.

What it teaches: PayPal is the warning label on Fundsmith's patience. A high-quality growth stock can become a lower-quality business or an overowned valuation story. The lesson is not that patience failed, but that the same patience that made Microsoft and Meta work can become dangerous if business quality changes.

Sources: Fundsmith annual letters 2017-2022, Q4 2021 SEC 13F, 2022 short-form report, Morningstar 2024, and Guardian 2024.

Near misses and exclusions

Becton Dickinson/CR Bard, Dr Pepper Snapple/Keurig Dr Pepper, Intuit, L'Oreal, Visa, ADP, Waters, and Alphabet all have credible cases, but the available evidence is either thinner, less clearly attributable to Smith's greatest wins, or still too live to rank above the eight trades above. Becton Dickinson/CR Bard is the strongest omitted medical-device complex, but the evidence is split across related issuers rather than a single clean stock trade. Intuit in particular is useful for sell-and-revisit discipline: Fundsmith sold after the Mailchimp acquisition, then rebuilt a stake in 2025 when the price better reflected the disappointment (2022 letter, 2025 short-form report).

Smithson, Fundsmith Emerging Equities Trust, Fundsmith Stewardship/Sustainable Equity, and the newer U.S. ETF are excluded from the ranked trades. They matter for the broader franchise record, but they are either not directly Terry Smith-managed public-equity trades, underperformed, were wound up/restructured, or are too young to judge (Smithson 2025 report, FEET final report, Fundsmith Stewardship factsheet, Fundsmith Equity ETF).

Cross-trade lessons

1. The best Fundsmith trades were not short-term catalysts. They were high-return businesses bought when controversy, strategic doubt, or boredom gave the fund a tolerable entry price.
2. Most of the gains came from doing less, not more: Microsoft, Stryker, IDEXX, Meta, and Philip Morris rewarded extended holding periods despite uncomfortable interim news.
3. Position liquidity matters. IDEXX and other large percentage ownership positions show why Fundsmith sometimes frames selling as costly not only because of taxes or bid/ask spreads, but because rebuilding a stake can be difficult.
4. The discipline is vulnerable to quality decay. Novo Nordisk and PayPal show that a business can start inside the quality bucket and later migrate toward a mistake if management execution, competition, or valuation changes.
5. Fundsmith's public record is easier to verify at the fund-attribution level than at the trade-ledger level. The honest evidence standard is contribution points, position snapshots, sale proceeds, and official commentary, not invented IRRs or P&L totals.

As of: 2026-07-03T21:20:46Z

Evidence note

This file covers Task D: major losses, errors of omission, near-death moments, what Smith/Fundsmith said about them, behavioral root causes, and process changes. The strongest evidence is official Fundsmith material: factsheets, annual and semiannual letters, reports, the Owner's Manual, prospectus, and Fundsmith-published papers. Independent checks come from Morningstar, Portfolio Adviser, AJ Bell, Trustnet, Interactive Investor, Companies House, FCA skilled-person guidance, Smithson/FEET primary documents, company releases, and one Fundsmith-linked Daily Telegraph Q&A whose exact Apple-regret wording is available through a public secondary transcript. Fundsmith does not publish a full trade ledger, stock-level cost basis, realized P&L, or internal investment memos, so stock-level mistakes are assessed through contribution tables, sale disclosures, 13F snapshots where relevant, manager commentary, company evidence, and independent criticism rather than invented IRRs or exact P&L.

No true fund-solvency or liquidity "near-death" event was found in the reviewed public sources. Fundsmith Equity's main damage case is a long relative-performance drawdown, not a run on the fund or vehicle failure. FEET and Smithson are therefore treated as Fundsmith-franchise and wrapper mistakes, with attribution caveats, rather than as Terry Smith flagship portfolio blow-ups.

Major losses, errors of omission, and near-death moments

1. The 2022-2026 flagship relative-performance drawdown

The central loss case is a multi-year stretch in which Fundsmith Equity's quality-growth discipline lagged global equities. The June 2026 factsheet shows the T Acc share class trailing the MSCI World GBP net comparator in 2022, 2023, 2024, 2025, and again year-to-date through 30 June 2026: -13.8% versus -7.8% in 2022, +12.4% versus +16.8% in 2023, +8.9% versus +20.8% in 2024, +0.8% versus +12.8% in 2025, and -2.9% versus +11.2% for the first half of 2026 (Fundsmith June 2026 factsheet). The same factsheet still shows a strong inception-to-date record of +592.6% cumulative and +13.1% annualised versus +530.9% and +12.5% for the comparator, which is why the fair framing is long relative-performance drawdown, not strategy collapse (Fundsmith June 2026 factsheet).

Compounding the official rows gives an approximate +3.3% Fundsmith cumulative return from 1 January 2022 to 30 June 2026 versus about +63.2% for MSCI World GBP net [calculated from factsheet rows]. Including 2021, the same arithmetic is roughly +26.1% versus about +100.5%. Fundsmith also states that the fund is not managed by reference to a benchmark, so the MSCI World numbers are comparator evidence rather than a mandate target (Fundsmith June 2026 factsheet).

Smith's explanation evolved but stayed internally consistent. In 2022 he emphasized rising rates and the end of easy money, arguing that Fundsmith's holdings remained profitable and cash-generative unlike many speculative growth stocks (Fundsmith 2022 annual letter). In 2023, he emphasized narrow Magnificent Seven and Nvidia-led market concentration; in 2024 and 2025, the explanation became more explicit about passive/index flows, AI-linked mega-cap leadership, and AI capital-expenditure uncertainty; the 2025 semiannual letter also cited dollar/currency effects (Fundsmith 2023 annual letter; Fundsmith 2024 annual letter; Fundsmith 2025 semiannual letter; Fundsmith 2025 annual letter).

The behavioral root cause is not recklessness but benchmark-independent conviction. The same independence that keeps Fundsmith from chasing fads can cause it to underreact if market leadership reflects a real structural shift. The process response so far has not been capitulation: Fundsmith has continued to emphasize quality, free-cash-flow conversion, low leverage, and long holding periods, while re-underwriting technology holdings where AI capital expenditure may change the asset-light economics that originally made them attractive. A 2026 Interactive Investor article reports that Microsoft and Meta exposure was roughly halved, but the official Fundsmith sources support the AI-capex underwriting concern more cleanly than the precise trade-rationale link (Fundsmith 2025 annual letter; Interactive Investor, 2026).

2. PayPal: a winner that became a late-exit warning

PayPal is the cleanest stock-level sell-discipline case. It had been a meaningful contributor, including +5.1% contribution in 2020, but became a detractor as customer engagement, management execution, acquisitions, and capital allocation came into question (Fundsmith 2020 annual letter; Fundsmith 2022 semiannual letter). The 2022 annual letter listed PayPal as a -2.5% detractor and records that Fundsmith sold it during the year (Fundsmith 2022 annual letter).

What Smith said was direct: PayPal had lost operational momentum and management focus. Portfolio Adviser reported Smith's criticism that PayPal seemed to be wasting an advantageous position, and Morningstar later cited PayPal as an example of a position sold too late after the thesis weakened (Portfolio Adviser, 2023; Morningstar, 2024).

The behavioral root cause was successful-holder inertia. A low-turnover process can be slow to admit that a former compounder has become a worse business. The process change is visible in later commentary: management quality and capital-allocation discipline became more explicit parts of the sell review, not just afterthoughts to high historical returns.

3. Estee Lauder, Amazon, and Adobe: sell discipline cuts both ways

Morningstar's 2024 downgrade matters because it did not simply say Fundsmith held losers too long. It argued that PayPal and Estee Lauder were sold too late, while Amazon and Adobe were sold too early or at least before subsequent AI-linked rebounds (Morningstar, 2024). Fundsmith's 2023 annual letter listed Estee Lauder as the largest detractor at -1.8%, citing China, travel-retail demand and supply, and supply-chain issues; Estee Lauder's FY2023 results independently corroborate weak sales and Asia travel-retail pressure (Fundsmith 2023 annual letter; Estee Lauder FY2023 results).

Amazon and Adobe should be framed as opportunity-cost and process-risk cases, not as quantified realized losses, because Fundsmith does not disclose full transaction-level ledgers. Amazon was a short-lived experiment after Fundsmith had long avoided it; Fundsmith bought Amazon in 2021 and sold it in 2023, with secondary coverage saying Smith objected to capital allocation around grocery expansion (Fundsmith 2021 annual letter; Fundsmith 2023 annual letter; Portfolio Adviser, 2023). Adobe raised thesis questions around the Figma acquisition, which was announced at about $20bn and later abandoned after competition scrutiny (Fundsmith 2022 annual letter; Adobe/Figma acquisition release, 2022; Adobe/Figma termination release, 2023; UK CMA Adobe/Figma case).

The root cause is asymmetry in regret. A quality investor can be too patient with thesis decay and too impatient with temporary controversy. The process problem is therefore harder than "trade more" or "trade less." The real question is what evidence proves that a company has left the quality universe.

4. Novo Nordisk and Coloplast: Danish quality as a management lesson

Novo Nordisk moved from a major Fundsmith winner into a live mistake case. It contributed positively in earlier years, but by 2025 it became central to underperformance. The 2025 annual letter recorded Novo as a -3.0% detractor and Coloplast as a -0.7% detractor, and Smith framed the problem as competition, illegal generic or compounding pressure, management execution, and acquisition/integration stress rather than ordinary share-price volatility (Fundsmith 2025 annual letter). Novo's own 2025 reporting discusses compounded semaglutide and commercial-execution issues, while Coloplast announced CEO Kristian Villumsen's departure in May 2025 (Novo Nordisk 2025 annual report; Coloplast CEO announcement, 2025).

The root cause was overreliance on business quality as a shield. A business can have high margins, a long runway, and strong market position yet still disappoint if management, pricing, competition, governance, or supply execution deteriorates. The process change is more explicit management-quality scrutiny and a clearer willingness to sell if engagement cannot repair the problem (Fundsmith 2025 annual letter).

5. Consumer staples: Brown-Forman, PepsiCo, Diageo, and thesis migration

Fundsmith's consumer-defensive mistakes are partly about changing categories. The 2025 letter records the sale of Brown-Forman and PepsiCo after Fundsmith saw structural pressure on alcohol and snacks from changing consumption patterns, GLP-1 appetite effects, and weaker growth prospects (Fundsmith 2025 annual letter). Brown-Forman's FY2025 results showed reported net sales down 5%, and PepsiCo's FY2025 release showed North American foods volume and profit pressure, which supports the deteriorating category backdrop (Brown-Forman FY2025 results; PepsiCo FY2025 results).

Diageo had already become a similar quality-thesis warning. Fundsmith's 2024 letter discussed concerns around new management, Latin America weakness, and the broader alcohol-demand issue; Diageo's FY2024 release also discussed Latin America and Caribbean weakness and inventory actions (Fundsmith 2024 annual letter; Diageo FY2024 results).

The behavioral root cause is category anchoring. Consumer brands that historically looked defensive can become lower-growth or more fragile when consumption changes. The process response is positive: Fundsmith sold well-known staples rather than defending them indefinitely because they used to be high-quality holdings.

6. Nvidia, AI, and the error of omission

Fundsmith's largest recent omission is not owning enough of the AI winners, especially Nvidia. Smith's 2024 letter defended not owning Nvidia on valuation, cyclicality, customer concentration, and AI-infrastructure return uncertainty, while acknowledging that narrow AI leadership had dominated index returns (Fundsmith 2024 annual letter). The 2024 semiannual letter likewise framed U.S. equity performance as highly concentrated in a few AI-linked stocks (Fundsmith 2024 semiannual letter).

This is not an admitted mistake under Smith's own philosophy. It is a strategy-risk case. A quality investor can be correct to avoid a stock that is too expensive or too hard to underwrite, yet still suffer major opportunity cost if the market leadership is real. The process change remains unresolved: Fundsmith did not buy the AI basket, but did re-underwrite Microsoft, Meta, and Alphabet exposure as AI capex raised questions about future free-cash-flow conversion. A secondary 2026 report says Fundsmith roughly halved Microsoft and Meta exposure; the official Fundsmith evidence supports AI-capex scrutiny, while the exact trade-rationale linkage remains secondary (Fundsmith 2025 annual letter; Interactive Investor, 2026).

7. Apple: the clean first-person omission regret

Apple is the cleanest admitted omission in the reviewed public material. Fundsmith's site links to a March 2024 Daily Telegraph Q&A with Smith, and a public transcript of that Q&A records that when asked whether he regretted any Fundsmith Equity investment decision, he answered: "Not owning Apple earlier" (Fundsmith/Daily Telegraph Q&A pointer, 2024; Acquirer's Multiple transcript, 2024).

This should be treated as an omission mistake, not a quantified trade. The public evidence found in this run does not disclose the hypothetical entry date, missed position size, or counterfactual P&L. The behavioral root cause is valuation and category caution inside a quality screen: an investor can correctly demand high returns on capital, cash generation, and durable intangible assets, yet still underappreciate the scale of an ecosystem compounder before it becomes obvious. No clear process change followed in the public record; the lesson is that omission errors in exceptional compounders can dominate visible stock-level losses.

8. FEET: the philosophy did not travel cleanly

Fundsmith Emerging Equities Trust is the clearest Fundsmith-franchise vehicle failure. FEET launched as an emerging-market application of the quality discipline, but was wound down after disappointing results. The 2014 prospectus presented Smith as personally leading the investment team and stock-selection process, but by the 2022 wind-up period the formal investment-manager review was signed by Michael O'Brien; attribution should therefore distinguish Smith's original process/brand role from later day-to-day management (FEET prospectus, 2014; FEET 2022 half-year report).

The final liquidators' report records a members' voluntary liquidation, with total distributions of GBP12.855 per ordinary share versus final NAV of GBP13.03; Companies House also records the process as members' voluntary liquidation, not creditor insolvency (FEET final report; Companies House FEET insolvency record). Trustnet reported the liquidation in the context of poor performance and Smith's comments on scale, fees, and capital (Trustnet, 2022). The final distribution gap versus pre-liquidation NAV also reflects wind-down and currency-realisation effects, so it should not be simplified into a clean stock-selection loss.

The root cause was transferability overconfidence. The same screen can work differently in markets with weaker governance, poorer disclosure, lower liquidity, more currency risk, and fewer globally dominant asset-light franchises. The process change was decisive: the vehicle was closed rather than preserved for brand pride.

9. Smithson: good-company investing met closed-end structure

Smithson was a subtler wrapper mistake. It applied a Fundsmith-like quality process to small and mid-cap companies through an investment trust. The 2026 circular names Simon Barnard as lead portfolio manager while Fundsmith LLP remains investment manager, so this is Fundsmith franchise/CIO oversight evidence, not direct Smith flagship-PM evidence (Smithson circular, 2026).

By 2026 the board proposed reconstruction into a UK OEIC. The circular says NAV per share total return was +57.0% since inception and -20.0% since the start of 2022, versus +87.6% and +27.0% for MSCI World SMID, and that more than GBP993m of buybacks had repurchased about 39.3% of shares outstanding as of 31 March 2022 without eliminating the discount (Smithson circular, 2026). The 2025 report and restructure materials reinforce that the issue was both performance and wrapper fit (Smithson 2025 report; Smithson restructure proposal).

The mistake was not only stock selection. It was vehicle design. A listed trust can trade at a discount independent of NAV, and buybacks may fail if investors lose confidence. The process change is structural: moving toward an OEIC to reduce the discount problem while keeping the investment approach. Attribution should stay at the Fundsmith founder/CEO/CIO/franchise-oversight level, not as a direct Terry Smith flagship-PM stock-picking error.

10. Unilever / GSK Consumer: public stewardship as a warning sign

Fundsmith's Unilever/GSK Consumer post mortem was a public critique of a portfolio company's capital allocation and communications rather than a quantified Fundsmith trading loss. It still matters because it shows a patient owner becoming publicly frustrated with management. Fundsmith criticized Unilever's failed GBP50bn approach for GSK Consumer Healthcare as strategically weak and poorly communicated, while Reuters-syndicated coverage reported Smith urging Unilever to focus on operating performance (Fundsmith Unilever/GSK post mortem, 2022; Reuters/MarketScreener, 2022).

The root cause was perhaps overpatience with a famous consumer franchise whose management and returns no longer matched the original quality ideal. The process response is visible in later consumer-staples sales: public engagement may be useful, but it is not a substitute for sale when the thesis has changed.

11. Regulatory and reputational scrutiny

This run found no public FCA or SEC enforcement action against Smith or Fundsmith in the reviewed official and secondary sources. The known regulatory item is press-reported Section 166 skilled-person review coverage. Portfolio Adviser reported that Fundsmith was required to undergo a review and later reported that recommendations were made but no further action was required; the FCA's own guidance describes skilled-person reviews as supervisory tools, not enforcement findings by themselves (Portfolio Adviser, May 2022; Portfolio Adviser, July 2022; FCA skilled-person reviews). Absence of a public enforcement hit is not a regulator certification; future checks should still review FCA/IAPD/Form ADV disclosures if legal status becomes material.

The reputational issue is underperformance under a simple, founder-led, mass-market brand. The Guardian tied the 2024 Morningstar downgrade to sell-discipline concerns, falling profits, investor withdrawals, and Smith's pay, while also noting Fundsmith's long-term outperformance defense (Guardian, 2024). Financial News reported large 2024 and 2025 outflows from the flagship, but those figures are secondary/paywalled and should be treated as lead-level evidence unless cross-checked against accounts or fund-flow datasets (Financial News, 2024; Financial News, 2025).

Morningstar's June 2026 review still retained a Silver rating, but flagged recent underperformance, a thinner bench, key-person risk, and the need for internal challenge (Morningstar, 2026). The root cause is the public-fund bargain: a simple, founder-led process is easy for clients to understand when it wins and easy to criticize when it lags.

Behavioral root causes across the mistakes

The first root cause is quality-label inertia. Once a company has earned a place in a concentrated low-turnover portfolio, the process can be slow to conclude that quality has eroded. PayPal, Estee Lauder, Novo, Coloplast, and some consumer holdings fit this pattern.

The second is benchmark-independent pride. Refusing to chase an index is essential to Fundsmith's identity, but it can become too easy to treat underperformance as market irrationality when the harder question is whether the opportunity set has changed.

The third is transferability overconfidence. Fundsmith's global large-cap quality screen did not automatically travel to emerging-market trusts, small/mid-cap closed-end format, or every consumer and healthcare subcategory.

The fourth is valuation ambiguity. Smith is right that good businesses deserve premium multiples, but Amazon, Adobe, Apple, Nvidia, Microsoft, and Meta show how hard it is to decide when price, quality, and runway no longer compensate each other.

Process changes made after

The clearest change is more explicit management-quality scrutiny. The Novo and Coloplast discussion shows that Fundsmith is less willing to assume an exceptional franchise can survive poor execution indefinitely (Fundsmith 2025 annual letter).

The second change is AI-capex re-underwriting. Official Fundsmith materials show explicit concern that AI infrastructure spending could lower future free-cash-flow conversion and returns on capital at Alphabet, Microsoft, and Meta; a secondary Interactive Investor report says Microsoft and Meta exposure was roughly halved, but that trade-rationale linkage should remain secondary-sourced (Fundsmith 2025 annual letter; Interactive Investor, 2026).

The third change is willingness to close or restructure weak vehicles. FEET was liquidated and Smithson moved toward an OEIC solution rather than preserving original wrappers at all costs (FEET final report; Smithson restructure proposal).

The fourth change is sharper consumer-staples skepticism. Brown-Forman, PepsiCo, and Diageo show a willingness to revisit old assumptions about alcohol, snacks, and brand resilience when consumer behavior changes (Fundsmith 2025 annual letter).

The unresolved change is sell discipline itself. Morningstar's critique is powerful because it says both too late and too early. The future evidence to watch is not whether Fundsmith trades more often, but whether it can distinguish temporary valuation pain from genuine quality decay with fewer large regret cases. Apple adds the mirror-image test: whether Fundsmith can identify exceptional quality early enough when valuation or category discomfort tempts omission.

What this teaches

Terry Smith's mistakes do not invalidate the Fundsmith doctrine. They make it more useful. A strategy built on high returns on capital, low leverage, concentration, low turnover, and accounting skepticism can still suffer from stale theses, style cycles, omitted winners, wrapper problems, and client-flow pressure. The practical lesson is that "buy good companies, don't overpay, do nothing" is incomplete until the investor defines what evidence proves a company is no longer good, what valuation makes a great business too expensive, what omitted compounder deserves active re-underwriting, and what vehicle gives the strategy enough time to work.

As of: 2026-07-03T23:29:57Z

Provenance Note

This file is a quote-verification map, not a quote-poster collection. I used short fragments only, kept each extract to 25 words or fewer, and preferred Fundsmith-hosted letters, Fundsmith-hosted articles, official Fundsmith documents, and edited interviews over quote aggregators. Third-party transcripts and AI-generated transcripts are marked as such. I did not use unattributed social-media quote cards, and I did not treat unofficial OCR of Accounting for Growth as Canon-safe page-level evidence.

Smith's own words cluster around a small set of recurring disciplines: quality first, valuation second, inactivity as a skill, accounting and leverage skepticism, low costs, benchmark independence, and the emotional difficulty of looking wrong for years.

1. Quality, Durability, And The Investable Universe

1. "Buy good companies / Don't overpay / Do nothing" (Fundsmith Equity Fund Owner's Manual, 2025)

2. "we seek to buy companies which deliver high returns on capital in cash." (Annual Letter to Shareholders, 2011)

3. "risk is better defined by the underlying characteristics of the companies" (Return Free Risk, 2013)

4. "Owning good companies is more important than owning undervalued companies." (The Market/NZZ interview, 2024)

5. "the vast majority of companies are uninvestable to us." (The Market/NZZ interview, 2024)

6. "a successful investment long before the words 'weight loss' were uttered" (Annual Letter to Shareholders, 2023)

The pattern is not merely "growth." Smith repeatedly narrows the investable universe to businesses that can convert returns on capital into cash, survive without financial leverage, and reinvest or distribute capital sensibly. The Novo Nordisk line from the 2023 letter is useful because it shows how he wants a holding to be judged: not by the most fashionable current narrative, but by the original business-quality thesis that existed before the headline catalyst.

2. Valuation, Benchmarks, And Market Timing

7. "we do not endeavour to track any index or to minimise our 'tracking error' versus any index" (Annual Letter to Shareholders, 2010)

8. "we do not seek to outperform in every reporting period or in all market conditions" (Annual Letter to Shareholders, 2012)

9. "whatever the outlook it will not alter our methodology of investment." (Annual Letter to Shareholders, 2013)

10. "we are at least one step ahead of most of them in recognising that we do not know what will happen." (Annual Letter to Shareholders, 2014)

11. "I know that I can't accomplish that successfully." (Annual Letter to Shareholders, 2015)

12. "No one can predict market downturns with any useful level of reliability." (Annual Letter to Shareholders, 2018)

13. "highly rated does not equate to expensive any more than lowly rated equates to cheap." (Annual Letter to Shareholders, 2019)

14. "I am not suggesting we will pay those multiples" (Annual Letter to Shareholders, 2021)

Smith's benchmark stance is explicit from the first annual letter: the index is an after-the-fact measuring stick, not an input into portfolio construction. His market-timing lines are also unusually blunt. The investor should not infer that Smith is indifferent to price; the 2019 and 2021 fragments show the more precise view. Cheap-looking shares can be expensive if the business is weak, and very high justified multiples are an analytical boundary, not an automatic purchase order.

3. Patience, Inactivity, Fees, And Capital Allocation

15. "we succinctly describe as 'do nothing'" (Annual Letter to Shareholders, 2016)

16. "minimising the costs of investment is a vital contribution to achieving a satisfactory outcome as an investor." (Annual Letter to Shareholders, 2017)

17. "fees produce a major drag on returns over time." (Fundsmith & Fees, 2010)

18. "It is unsupportable." (Fund Management Fees - Two and Twenty, 2010)

19. "Capital allocation decisions are amongst the most important decisions" (Share Buybacks: Friend or Foe?, 2011)

20. "Large friendly acquisitions rarely deliver value for shareholders." (Unilever + GSK Consumer: A Post Mortem, 2022)

21. "The day job is not glamorous." (Richer, Wiser, Happier / TIP interview, 2025)

The "do nothing" phrase can be overread. In the cited 2016 letter, Smith uses it as shorthand for low turnover and deliberate inactivity, not as a rule never to sell: do not churn merely to look busy, do not pay unnecessary transaction and management costs, and let management's capital-allocation record affect whether a company stays eligible. The Unilever/GSK note is especially useful because it shows the negative side of his patience: when management tries to solve weak growth through a large friendly acquisition, he treats that as a red flag, not as a harmless strategic option.

4. Accounting, Leverage, And Business Reality

22. "I never invest in anything that requires leverage to make an adequate return." (Why I never invest in bank shares, 2023)

23. "Retailer's returns on capital have been falling for years" (How investors ignored the warning signs at Tesco, 2014)

24. "major costs were being ignored in the calculation of profits." (AstraZeneca is beginning to look like Tesco, 2017)

25. "Detail is a perfectly good word." (Banned Words and Phrases, 2013)

Smith's accounting voice predates Fundsmith; this pass treats Accounting for Growth only as bibliographic context until page-level verification is available. The strongest public, linkable evidence came from Fundsmith-hosted essays rather than the book text itself. These quotes show the same thread: beware leverage that manufactures returns, watch returns on capital before the crisis becomes obvious, and resist managerial language that hides economic reality. The book Accounting for Growth belongs in the index below, but direct book quotations should be added only after page-level verification from a legitimate copy.

5. Underperformance, Mistakes, Independence, And AI

26. "An explanation is not an excuse." (Annual Letter to Shareholders, 2025)

27. "You make money with old friends" (Annual Letter to Shareholders, 2024)

28. "PayPal seems intent on snatching defeat from the jaws of victory." (Annual Letter to Shareholders, 2022)

29. "AI may not be of immediate and/or universal benefit" (Annual Letter to Shareholders, 2024)

30. "Far from being passive, this makes them a momentum strategy." (Annual Letter to Shareholders, 2025)

31. "We're not AI deniers." (Fundsmith 2026 AGM transcript, Steady Compounding, 2026)

32. "the psychological pressure is considerable." (Fundsmith 2026 AGM transcript, Steady Compounding, 2026)

The post-2021 period gives the cleanest test of whether Smith's language is merely promotional. In 2022 he criticized PayPal management; in 2024 and 2025 he pushed back on AI extrapolation and index concentration; in 2025 he wrote the important boundary line that explanation is not excuse. The Steady Compounding 2026 transcript should be treated as a secondary transcript tied to a public AGM video, useful for leads and short snippets but still inferior to Fundsmith's own written materials for exact wording.

Annotated Primary-Materials Index

1. Fundsmith documents archive - Official master index for Fundsmith Equity Fund letters, reports, Owner's Manual, and public papers.

2. Fundsmith Equity Fund Owner's Manual, 2025 - Best concise source for the three-part maxim, investor-behavior warning, low-turnover philosophy, market-timing limits, and fee alignment.

3. Annual Letter to Shareholders, 2010 - Establishes the no-benchmark-construction stance and early ETF/passive skepticism.

4. Annual Letter to Shareholders, 2011 - Useful on cash returns on capital, buybacks, and reinvestment risk.

5. Annual Letter to Shareholders, 2012 - Explicitly warns shareholders not to expect outperformance in every reporting period.

6. Annual Letter to Shareholders, 2013 - Strong statement that macro outlook does not alter investment method.

7. Annual Letter to Shareholders, 2014 - Anti-forecasting humility and process consistency during market commentary.

8. Annual Letter to Shareholders, 2015 - Clean source for Smith's refusal to rely on successful market timing.

9. Annual Letter to Shareholders, 2016 - Best annual-letter source for "do nothing" and low turnover as a deliberate act.

10. Annual Letter to Shareholders, 2017 - Cost discipline and the drag from portfolio turnover.

11. Annual Letter to Shareholders, 2018 - Market-downturn prediction skepticism and long-horizon framing.

12. Annual Letter to Shareholders, 2019 - Good source for the distinction between high multiples and expensive securities.

13. Annual Letter to Shareholders, 2020 - Pandemic-year letter; useful context for quality-business resilience and portfolio behavior in stress.

14. Annual Letter to Shareholders, 2021 - Shows Smith's valuation framework before the post-2021 growth-stock reset.

15. Annual Letter to Shareholders, 2022 - Best primary source on the PayPal mistake, Unilever engagement, and criticism that Fundsmith had become a "tech fund."

16. Annual Letter to Shareholders, 2023 - Useful for Magnificent Seven/AI context, Novo Nordisk thesis defense, and Estee Lauder sale rationale.

17. Annual Letter to Shareholders, 2024 - Strong on AI caution, repeated contributors, Nvidia skepticism, and why the fund will not simply buy benchmark winners.

18. Annual Letter to Shareholders, 2025 - Essential current source on underperformance, passive/index concentration, AI capex skepticism, and dollar weakness.

19. Semi Annual Letter to Shareholders, 2025 - Midyear performance and portfolio update; useful for current-state context but thinner than annual letters.

20. Return Free Risk, 2013 - Core essay arguing that equity risk is better understood through business characteristics than volatility alone.

21. Fund Management Fees - Two and Twenty, 2010 - Early public critique of hedge-fund fee structure.

22. Fundsmith & Fees, 2010 - Short, direct explanation of fee drag and why costs matter to compounded returns.

23. Share Buybacks: Friend or Foe?, 2011 - Source for Smith's capital-allocation lens and skepticism toward buyback accounting optics.

24. Banned Words and Phrases, 2013 - Reveals the accounting-language and disclosure instincts behind his style.

25. How investors ignored the warning signs at Tesco, 2014 - Public-company diagnostic case study built around falling returns on capital.

26. AstraZeneca is beginning to look like Tesco, 2017 - Accounting-quality critique, especially around ignored costs in profit presentation.

27. Unilever + GSK Consumer: A Post Mortem, 2022 - Co-authored by Smith and Julian Robins; useful on acquisitions, capital allocation, and why the Unilever/GSK approach troubled them.

28. Why I never invest in bank shares, 2023 - Best concise source for leverage aversion and the bank-sector exclusion.

29. The Market/NZZ interview: Valuation Is Not as Important as Quality, 2024 - Edited Q&A; strong near-primary source on quality versus valuation, sector exclusions, and the limited investable universe.

30. Interactive Investor: 100th episode special - the Terry Smith interview, 2024 - Full interview transcript; useful on passive investing, underperformance, sell discipline, Diageo, Nvidia, and buybacks.

31. Money Maze Podcast: Is Active Management Worth Paying For?, 2024 - Fundsmith-hosted show page; use as an audio/video lead only because no usable transcript was verified in this pass.

32. Richer, Wiser, Happier / TIP: Billionaire Brit w/ Terry Smith, 2025 - Long-form interview with transcript; useful for temperament and process, but transcript is AI-generated and should be checked before heavy quotation.

33. Bentley Reid: Expert Insights with Terry Smith, 2025 - Fundsmith-hosted video lead; useful as a primary video source when exact lines are video-verified.

34. Fundsmith TV / Annual Shareholders' Meeting, 2026 - Official video hub for the AGM; best primary location for Q&A tone and live shareholder explanations.

35. Steady Compounding transcript: Fundsmith Annual Meeting, 2026 - Third-party transcript of public AGM; useful for locating quotes but should be checked against video for final page-level precision.

36. Behind the Balance Sheet: The Pugilist, 2026 - Host-published interview transcript on underperformance psychology, passive investing, AI, accounting, and Smith's background; visibly noisy, so exact wording needs audio verification.

37. Investing for Growth, second edition - publisher page - Bibliographic anchor for Smith's collected writings through 2025; useful for mapping essays to canonical print form.

38. Accounting for Growth - Internet Archive record - Bibliographic anchor for Smith's accounting classic; access-restricted in this pass, so no direct quote should be treated as verified from it without a legitimate page check.

Attribution Watchlist

• Do not use the common "quality companies at reasonable prices" formulation as a Terry Smith quote unless a primary source is found; it is better treated as a paraphrase.
• The exact wording of the maxim should be cited to the Owner's Manual. Prefer "buy good companies, don't overpay, do nothing" over looser circulating versions.
• Do not import punchy lines from quote sites, LinkedIn posts, YouTube shorts, or aggregator snippets unless they trace back to Fundsmith letters, Fundsmith documents, edited interviews, AGM video, or a page-verified book source.
• Accounting for Growth is important, but this pass found only metadata and unofficial OCR access. Add page-level book quotes later if a legitimate scan or physical copy is checked.
• Steady Compounding transcripts and AI-generated podcast transcripts are helpful leads. They should remain marked as secondary unless the exact audio/video is independently checked.

As of: 2026-07-03T17:44:05Z

Scope and evidence caveats

Terry Smith's written record is unusually useful because it spans three connected genres: the 1992 accounting book that made his reputation, the Fundsmith operating documents that state the investment contract, and a long run of letters and essays that show the method under pressure. The primary-source base for this file is therefore Smith-authored or Fundsmith-published material wherever possible: Accounting for Growth, Investing for Growth, the Fundsmith Equity Fund Owner's Manual, annual letters, Fundsmith-hosted Financial Times essays, and selected Fundsmith papers.

There are two caveats. First, Accounting for Growth is access-restricted in the Internet Archive scan used for bibliographic confirmation, so this file relies on catalog metadata and Smith's later own descriptions of the book rather than unverifiable page quotations from the scan Internet Archive, 1996 edition. Second, Investing for Growth is an anthology, so many chapters are better read in their original Fundsmith-hosted form when available. The 2026 second edition adds material from 2020-2025 and is treated as current bibliographic evidence, not as independently page-verified chapter text Harriman House, second edition.

Works by Terry Smith

1. Accounting for Growth: Stripping the Camouflage from Company Accounts (1992; second edition 1996)

Central thesis: reported accounting profits are often a managed presentation, not an economic truth. Smith's core claim is that investors should strip away accounting camouflage before judging growth, returns on capital, and valuation. The Internet Archive catalog describes the 1996 edition as a 216-page Century Business book on accounting and financial statements; it notes that the 1996 edition followed the 1992 original Internet Archive.

Key ideas:

1. EPS growth can mislead if it is purchased with more capital at lower returns. Smith's later Tesco essay is the practical extension of the book's logic: Tesco reported rising EPS while returns on capital deteriorated, and Smith treats that gap as a warning sign investors ignored Tesco essay.
2. Adjusted earnings deserve suspicion when the adjustments mostly remove bad news. Smith's 2015 Financial Times essay revisits the Accounting for Growth thesis by criticizing "adjusted", "core", and "underlying" profit measures that exclude recurring economic costs Cooking the books essay.
3. Cash flow is not automatically clean; the cash-flow statement also needs interpretation. In the 2022 annual letter he argues that share-based compensation can distort operating cash flow when treated as a non-cash add-back rather than a financing cost 2022 annual letter.
4. Good accounting analysis is tied to capital allocation. Smith is not looking for accounting foot-faults in isolation; he is trying to decide whether managers earn high returns, deploy incremental capital wisely, and avoid value-destructive deals.
5. The book's career significance matters because it shows Smith's willingness to publish adverse analysis despite institutional pressure. Harriman House's author note says he was dismissed in 1992 after the book's publication and later built Collins Stewart and Tullett Prebon Harriman House.

Best chapters or sections to read: the exact chapter layout still needs page-level verification against a borrowed or physical copy. For Canon purposes, the priority is to page-check the sections on earnings manipulation, acquisition accounting, goodwill, pension and lease obligations, capitalized costs, and cash-flow quality. Until that is done, pair the book with Smith's later Tesco, pharmaceuticals, and share-based-compensation essays because they show how the same diagnostic habit appears in live investment decisions.

2. Investing for Growth: How to make money by only buying the best companies in the world (2020; second edition 2026)

Central thesis: Smith's investment doctrine is deliberately simple - buy good companies, do not overpay, and then let compounding work. The 2026 Harriman House page describes the second edition as an anthology of essays and letters from 2010-2025, with new 2020-2025 material and a Lionel Barber foreword Harriman House. The publisher's page explicitly summarizes the book's themes as quality businesses, cash generation, reinvestment, and debunking investing myths.

Key ideas:

1. Good companies matter more than headline cheapness. Smith's 2015 five-year Fundsmith essay argues that long-term returns are driven more by owning good businesses than by whether the initial rating looked optically cheap Five-year essay.
2. Compounding comes from retained earnings reinvested at high returns, not just reinvested dividends. The 2017 equity-compounding essay explains why equities have a structural advantage over bonds and real estate when companies retain capital at attractive returns Unique advantage essay.
3. Market timing is usually a behavioral trap. The 2013 "Ten golden rules" essay states the private investor version of the doctrine: understand what you own, avoid timing, minimize fees, and stop trading unnecessarily Ten golden rules.
4. Fee drag is an investment fact, not a moral complaint. Smith's early "Two and Twenty" paper attacks hedge fund fee structures because fee extraction changes the compounding arithmetic for clients Two and Twenty.
5. Share buybacks are capital-allocation decisions, not automatically shareholder-friendly acts. The 2011 paper argues that buybacks should be judged by valuation, alternative uses of capital, and returns, not by EPS optics Share Buybacks.
6. Words matter because language often reveals weak economics. The 2013 "Banned Words" paper flags management language that can obscure economics or excuse poor capital allocation Banned Words.
7. The later edition should be read as a live anthology, not a settled theory. Its 2020-2025 update captures pandemic-era accounting questions, technology valuations, inflation, index concentration, and recent Fundsmith underperformance.

Best chapters or sections to read: start with the Owner's Manual-like chapters that set out the three-part strategy, then read "Two and Twenty", "Share Buybacks", "Lessons from the Tour de France", "Ten golden rules", "The Unique Advantage of Equity Investing", the annual letters from 2020-2025, and the essays on banks, pharmaceuticals, Tesco, Unilever/GSK, and share-based compensation. Those chapters show the doctrine moving from slogan to accounting and capital-allocation practice.

3. Fundsmith Equity Fund Owner's Manual (latest observed 2025)

Central thesis: the Owner's Manual is the closest thing Smith has to an investment contract with clients. It tells investors what Fundsmith will try to do, what it will avoid, and how clients should judge the fund. Fundsmith's documents page says the Owner's Manual is intended to explain what the firm is trying to achieve and how it will approach that goal Fundsmith documents. The PDF lays out sections on the investment management industry, how Fundsmith invests, the fund manager, and fees Owner's Manual.

Key ideas:

1. Risk-adjusted long-term return is the goal, not the best short-period return.
2. Fundsmith aims to buy and hold high-quality businesses, not trade macro forecasts.
3. The businesses must generate high returns, have intangible or difficult-to-replicate assets, avoid the need for high leverage, and have growth potential.
4. Valuation still matters: quality is necessary but not sufficient.
5. Fundsmith will tolerate benchmark divergence and concentrated ownership if the companies meet the quality bar.
6. The document prepares investors for periods when the strategy lags fashionable or momentum-driven markets.

Best sections to read: "How we invest at Fundsmith" is the essential core. The subsections on avoiding leverage, rejecting Greater Fool Theory, not attempting market timing, not over-diversifying, and not fixating on benchmarks are the cleanest summary of the method. The fee section is also important because it connects Smith's anti-fee writing to the actual product structure.

4. Fundsmith Equity Fund annual letters (2010-2025)

Central thesis: the annual letters are Smith's best longitudinal writing. They document performance, portfolio evolution, recurring mistakes, and changes in the opportunity set while holding the strategy constant. Fundsmith's documents page indexes annual letters from 2010 through the 2025 letter dated January 2026 Fundsmith documents.

Key ideas:

1. The letters turn philosophy into a scorecard. The 2024 letter restates the three-step strategy and then tests the portfolio against ROCE, gross margin, operating margin, cash conversion, and interest cover 2024 annual letter.
2. They distinguish company fundamentals from share-price narratives. The 2022 letter argues that quality companies can be marked down with lower-quality growth stocks during risk-off markets, but the underlying business quality still matters 2022 annual letter.
3. They revisit accounting issues as new market fashions appear. The 2022 letter's share-based-compensation section is a late-career extension of Accounting for Growth.
4. They expose the cost of concentration and style. The 2025 letter reports 2025 underperformance against MSCI World and attributes the pressure to index concentration, passive flows, and dollar weakness while explicitly refusing to turn Fundsmith into a momentum strategy 2025 annual letter.
5. They provide a record of sell discipline. The letters explain sales and trims, but also show the tension that Morningstar later highlights: the strategy wants to run winners, but position sizing and stale theses still require judgment.

Best letters to read: 2010 for the founding intent; 2012 and 2014 for early process discipline; 2018 for inactivity as a virtue; 2021 for the "companies not countries" framing; 2022 for inflation, share-based compensation, and technology classifications; 2024 for the cleanest numerical portfolio scorecard; 2025 for the best current defense of the strategy during underperformance.

5. Fundsmith-hosted accounting and business-quality essays

Central thesis: these essays are Smith's shorter case studies in how to read businesses. They are more valuable than generic interviews because they show what evidence Smith thinks should change an investor's mind.

Key ideas:

1. Tesco is the canonical "bad accounting signal" case. Smith argues investors focused on EPS and ignored falling ROCE plus repeated changes in the ROCE definition Tesco essay.
2. The 2015 pharmaceuticals/accounting essay warns that non-GAAP "core" measures can make recurring costs disappear from valuation analysis Cooking the books essay.
3. The 2017 AstraZeneca essay applies a similar lens to acquisition accounting, recurring exceptional items, and return on capital AstraZeneca essay.
4. The 2023 bank-shares essay shows the negative screen: Smith will not own businesses that require high leverage to earn acceptable equity returns Bank shares essay.
5. The 2015 five-year essay is a bridge between accounting and portfolio behavior: read the accounts, stick with facts over market opinion, and be slow to sell good companies Five-year essay.

Best sections to read: read Tesco first, then "Why bother cooking the books", then the 2022 annual letter's share-based-compensation section, then the bank-shares essay. Together they form a compact version of Smith's accounting curriculum.

6. Papers on investor behavior, fees, and capital allocation

Central thesis: Smith's quality strategy depends as much on avoiding preventable errors as on finding superior companies. These papers identify errors in incentives, trading behavior, management language, and buyback logic.

Key ideas:

1. "Two and Twenty" frames fees as a structural hurdle to client compounding Two and Twenty.
2. "Share Buybacks" treats repurchases as capital allocation subject to expected return, not as automatic EPS enhancement Share Buybacks.
3. "Lessons from the Tour de France" turns a sporting analogy into a portfolio lesson: investors do not need to win every stage to win the long race Lessons from the Tour de France.
4. "Return Free Risk" challenges the idea that higher risk mechanically earns higher return Return Free Risk.
5. "Banned Words" is a checklist for detecting language that substitutes story for economics Banned Words.
6. "The Unique Advantage of Equity Investing" is the best short piece on why high-ROCE retained earnings are the core of Smith's compounding model Unique advantage essay.

Best sections to read: "The Unique Advantage" should be read in full. Then read "Share Buybacks" and "Banned Words" as capital-allocation and language checklists. "Two and Twenty" is most useful as a companion to the Owner's Manual fee section.

7. Unilever + GSK Consumer: A post mortem (2022, Fundsmith)

Central thesis: this paper is an activist-quality case note wrapped in long-only language. It argues that Unilever's attempted GSK Consumer transaction revealed poor capital-allocation judgment, weak communication with long-term shareholders, and insufficient attention to historical business performance Unilever/GSK post mortem.

Key ideas:

1. A long-term shareholder can be patient without being passive.
2. Management should be judged on long-term operating performance, not on a short burst of reported sales growth.
3. Strategic deals need a return-on-capital case, not just scale or narrative appeal.
4. Investor relations is part of governance, especially when major shareholders have held through difficult periods.
5. The paper shows Smith's doctrine applied to ownership behavior, not only security selection.

Best sections to read: the opening "Why publish a post mortem?" section explains the purpose; the performance comparison section shows why Fundsmith was dissatisfied; the communication and strategic-rationale sections show how Smith translates investment analysis into stewardship.

Best works about Terry Smith

1. Morningstar's 2026 Fundsmith Equity review. This is the most useful current third-party assessment because it separates praise for the philosophy from concerns about recent underperformance, outflows, portfolio shape, position sizing, and sell discipline. Morningstar still describes the process as simple and well-articulated, but it highlights the tension created by a concentrated quality-growth approach in narrow bull markets Morningstar 2026 review.
2. Morningstar's 2024 downgrade from Gold to Silver. The downgrade is important because it is not a rejection of Smith's philosophy; it is a warning that execution questions had become more material, especially sell discipline and the free-cash-flow-yield gap versus indices Morningstar downgrade.
3. Publisher and catalog pages for Accounting for Growth and Investing for Growth. The Harriman House page is useful for current bibliographic data, the 2026 edition, and a concise biography that links the 1992 book to Smith's later career Harriman House. The Internet Archive page is useful for the 1996 edition's publisher, ISBN, page count, topics, and access restrictions Internet Archive.
4. Fundsmith's own document archive. It is a primary-source index rather than analysis, but for researchers it is the canonical map of Owner's Manuals, annual letters, reports, and papers Fundsmith documents.
5. Long-form interviews and transcripts. The best use of interviews is to supplement, not replace, the writings. The Market/NZZ interview is useful for how Smith talks about quality versus valuation The Market/NZZ via Fundsmith. The Richer Wiser Happier episode is useful for biography and temperament, but transcript quality should be checked against the audio before relying on exact wording Richer Wiser Happier.

Reading order for the Canon

1. Start with the 2025 Owner's Manual to understand the client contract and the negative screens Owner's Manual.
2. Read the 2024 annual letter for the cleanest portfolio scorecard and the 2025 annual letter for the current stress test during underperformance 2024 annual letter, 2025 annual letter.
3. Read the accounting sequence: Accounting for Growth metadata, Tesco, "Why bother cooking the books", the 2022 share-based-compensation section, and the bank-shares essay Internet Archive, Tesco essay, Cooking the books essay, 2022 annual letter, Bank shares essay.
4. Read Investing for Growth as an anthology, using original Fundsmith URLs where available Harriman House.
5. Finish with Morningstar's 2024 and 2026 critiques so Smith's self-description is tested against a current outsider's view Morningstar downgrade, Morningstar 2026 review.

Open verification tasks

1. Page-check the 1992 and 1996 editions of Accounting for Growth against a borrowed or physical copy. This file should not treat its chapter-level reconstruction as definitive until that is done.
2. Page-check the 2020 and 2026 editions of Investing for Growth against physical or publisher-provided copies. The chapter list is partly inferred from original articles and publisher descriptions.
3. Verify interview transcripts against audio before extracting exact quotations. The most useful interviews are secondary to the written corpus for this task.
4. Continue separating Terry Smith's own writing from Fundsmith franchise materials, especially Smithson and Fundsmith ETF documents where Smith may not be the sole author or portfolio decision-maker.

As of: 2026-07-03T18:36:30Z

Evidence note

This file reconstructs Terry Smith's mental models from completed Canon files A, B, C, and F, plus fresh source checks for Task G. Tasks D and E for this investor were still freshly claimed and unavailable at the time of writing, so this document should be refreshed after those files close if they add new mistakes, direct quotes, or transcript evidence. The strongest evidence base is Smith/Fundsmith primary material: the Owner's Manual, prospectus, annual letters, factsheets, accounting essays, and Fundsmith papers. Independent sources are used mainly to test failure modes and transferability.

Named heuristics & frameworks

1. Buy good companies, don't overpay, do nothing

Smith's best-known model is a three-part discipline: own exceptional businesses, pay a price that allows future compounding to show through, and then keep trading friction low. Fundsmith's annual letters use that structure as the organizing frame for judging portfolio quality, valuation, and turnover (Fundsmith 2025 annual letter, 2026; Fundsmith 2024 annual letter, 2025). The phrase is simple, but it is not a generic quality slogan. It embeds three tests: whether the business is genuinely superior, whether the prospective free-cash-flow return is adequate, and whether the investor can resist activity once the thesis is intact.

The model's practical implication is that research time is front-loaded. A stock that passes should require fewer decisions later; a stock that needs constant macro, regulatory, or balance-sheet updates probably never fit the process. This explains why Fundsmith treats low turnover as an outcome of prior selectivity, not as an independent virtue. In 2024 the flagship reported 3.2% turnover and 0.002% voluntary dealing cost; in 2025, after several sales, turnover was still only 12.7% and voluntary dealing cost was 0.008% (Fundsmith 2024 annual letter, 2025; Fundsmith 2025 annual letter, 2026).

2. The cash-return test

Smith's quality definition begins with cash return on operating capital, not EPS growth. The Owner's Manual defines the target company as one with high return on operating capital employed in cash, and the annual scorecards report look-through return on capital employed, gross margin, operating margin, cash conversion, and interest cover (Fundsmith Owner's Manual, 2025; Fundsmith 2025 annual letter, 2026). In the 2025 letter, Fundsmith reported portfolio ROCE of 31%, gross margin of 62%, operating margin of 28%, cash conversion of 94%, and interest cover of 29x (Fundsmith 2025 annual letter, 2026).

This is an accounting-forensics model turned positive. Smith's Accounting for Growth reputation came from challenging reported profit quality, and his later Tesco and AstraZeneca essays apply the same habit to live companies: rising EPS is not persuasive if return on capital falls, cash flow is weak, debt rises, "core" earnings exclude recurring costs, or management changes definitions in ways that flatter results (Accounting for Growth catalog, 1996 edition; Tesco essay by Smith, 2014; AstraZeneca essay by Smith, 2017).

3. Intangible franchise before asset backing

Smith looks for businesses whose important assets are hard to replicate and often under-recorded by accounting. The Owner's Manual lists brands, dominant market positions, patents, distribution networks, installed bases, and customer relationships as examples of intangible assets that can support persistent high returns (Fundsmith Owner's Manual, 2025). This helps explain holdings such as IDEXX, Stryker, Microsoft, Meta, and Philip Morris: the thesis is not that they are cheap on book value, but that their economic positions can prevent normal competitive mean reversion.

The model treats durability as a research question. A brand, network, patent estate, or distribution system is useful only if it lets the company reinvest incremental cash at high returns. Fundsmith therefore pairs the moat story with quantitative checks on cash conversion and return on operating capital. A narrative that does not survive the cash-return test is not a Smith-style moat.

4. Leverage is a negative screen, not a valuation input

Smith is unusually clear that some businesses are excluded before valuation. The Owner's Manual says Fundsmith avoids companies that require borrowed money to earn adequate returns, and Smith's bank essays explain why he will not own banks: high balance-sheet leverage means small asset losses can wipe out equity, while panic and regulation can damage even competent institutions (Fundsmith Owner's Manual, 2025; Bank shares essay by Smith, 2014; Bank shares essay by Smith, 2023).

This is more than balance-sheet conservatism. It narrows the investable universe away from banks, many insurers, credit businesses, leasing, real estate, capital goods, transport, utilities, commodity businesses, and cyclicals whose returns depend on leverage, regulation, or cycles. The point is to avoid needing a heroic credit-cycle forecast.

5. Reinvestment runway over dividend yield

Smith's compounding model depends on companies retaining cash and reinvesting it at high incremental returns. His "unique advantage of equity investment" argument is that equities can compound in a way bonds and real estate generally cannot when retained earnings are redeployed at high returns (Unique Advantage essay by Smith, 2017). The Owner's Manual similarly emphasizes companies that can reinvest cash flows to grow while maintaining high returns (Fundsmith Owner's Manual, 2025).

This model also explains why capital allocation is central. Buybacks are judged by price and opportunity cost, not by EPS optics; acquisitions are judged by return on incremental capital, not strategic language. Smith's Unilever/GSK Consumer post mortem criticized management because the proposed deal appeared to need large performance improvements to justify the price, and the return case was not made clearly to shareholders (Share Buybacks paper, 2011; Unilever/GSK post mortem, 2022).

6. Free-cash-flow yield is the valuation anchor

Smith does not ignore valuation; he tries to anchor it in free cash flow rather than accounting earnings. The 2025 letter reported Fundsmith's portfolio free-cash-flow yield rising from 3.1% to 3.7%, compared with 2.8% for the S&P 500 and 3.1% for MSCI World, and used those comparisons to argue that the portfolio was not simply a basket of expensive quality stocks (Fundsmith 2025 annual letter, 2026).

The free-cash-flow-yield model creates a practical tension: an exceptional business can still be a poor investment at too high a price, but selling too early can be worse than paying up for quality. Domino's Pizza is the cleanest lesson from the trade record. Fundsmith sold after a large early rise and later acknowledged regret when the business kept compounding, showing that valuation discipline can create opportunity-cost errors as well as prevent overpayment (Fundsmith 2011 annual letter; Fundsmith 2016 annual letter).

7. Language is evidence

Smith treats management language as a clue to capital-allocation quality. His "Banned Words" paper turns jargon, euphemism, and vague corporate abstractions into warning signs, and the Unilever/GSK paper applies a similar lens to words such as "agility" and "focus" when they substitute for hard return logic (Banned Words paper, 2013; Unilever/GSK post mortem, 2022). This is not a standalone screen, but it is a useful diagnostic: managers who cannot explain economics plainly may also be hiding weak economics or confused strategy.

8. Benchmark independence as a risk model

Fundsmith frames benchmark divergence as necessary, not accidental. The Owner's Manual rejects index hugging and excessive diversification, while the 2025 annual letter argues that owning every Magnificent Seven stock at benchmark weight would be too much portfolio risk even if the companies were good (Fundsmith Owner's Manual, 2025; Fundsmith 2025 annual letter, 2026). The June 2026 factsheet showed 31 holdings and 88% active share as of December 2024, underlining that the fund is built to differ from the index (Fundsmith June factsheet, 2026).

This is also where the model hurts. If a narrow group of index giants drives returns for years, Fundsmith can look wrong even while its companies remain profitable. The model therefore needs investors who can distinguish business quality from benchmark-relative pain, and managers who can tell when divergence is justified versus stale.

Their decision checklist, reconstructed

Screens

1. Require high cash returns on operating capital, durable gross and operating margins, high cash conversion, and conservative interest cover (Fundsmith 2025 annual letter, 2026).
2. Demand a hard-to-replicate franchise: brand, market position, installed base, patent, distribution network, customer relationship, or similar durable asset (Fundsmith Owner's Manual, 2025).
3. Reject companies whose return model requires significant leverage, commodity/cycle timing, regulated balance-sheet leverage, or heroic refinancing (Fundsmith Owner's Manual, 2025; Bank shares essay by Smith, 2023).
4. Require a plausible reinvestment runway: the company should be able to deploy retained cash at attractive returns rather than merely distribute it (Unique Advantage essay by Smith, 2017).
5. Avoid accounting presentations where adjusted profit, recurring exceptional items, stock compensation, acquisition accounting, leases, or changing definitions make reported profit diverge from economic cash flow (Cooking the Books essay by Smith, 2015; Fundsmith 2022 annual letter).

Research

The research habit is to read the accounts first, then the story. A Smith-style analyst should trace profits into free cash flow, reconcile capital employed to the return claim, include debt-like items such as leases, study whether capitalized costs or stock compensation flatter cash flow, and compare management language with actual returns. Tesco is the template for this forensic work: EPS was rising, but Smith argued that return on capital, definition changes, free cash flow, and debt were flashing warnings (Tesco essay by Smith, 2014).

The second research layer is business durability. Microsoft and Meta show the model at work in technology: both were held through drawdowns because Fundsmith judged the franchises to remain strong, but both were later trimmed when AI capital expenditure raised questions about future returns on capital (Fundsmith 2022 annual letter; Fundsmith 2025 annual letter, 2026; Interactive Investor, 2026).

Valuation and entry

Entry discipline centers on whether the free-cash-flow yield and expected growth compensate for durability risk and alternatives. Smith's own letters compare portfolio free-cash-flow yield with market yields, while independent critics have focused on whether that valuation cushion has been sufficient during the post-2021 lag (Fundsmith 2025 annual letter, 2026; Morningstar downgrade, 2024).

The entry rule is not "buy quality at any price." It is closer to: buy only if the business can compound cash at high returns for long enough that today's free-cash-flow yield understates the future owner return. The danger is that duration becomes a license to rationalize any multiple.

Sizing and portfolio construction

Fundsmith's normal range is about 20-30 stocks; the June 2026 factsheet reported 31 holdings, 7.0% cash, GBP12.3 billion fund size, and 93% seven-day fund liquidity (Fundsmith June factsheet, 2026). The UCITS prospectus supplies hard limits: spread rules generally cap single-issuer exposure at 10%, and positions over 5% are constrained by the 40% basket rule (Fundsmith prospectus, 2026).

Exact position-sizing formulas are not disclosed. The observable rule is to concentrate in the best-qualified businesses, tolerate large benchmark differences, keep liquidity adequate for an open-ended fund, and trim when either valuation, capital intensity, or portfolio risk becomes excessive. The Microsoft and Meta reductions by late 2025 and early 2026 are examples of size reset after AI capex changed the risk/reward question; 13F filings show lower U.S. reportable stakes, but those filings do not show cost basis, non-U.S. ordinary shares, intra-quarter trades, cash, or realized P&L (SEC Fundsmith LLP 13F Q1 2026; SEC 13F FAQ).

Sell rules

The reconstructed sell checklist has five triggers:

1. The company's quality deteriorates: margins, cash conversion, return on capital, competitive position, or management execution no longer match the original underwriting.
2. The reinvestment runway deteriorates: growth requires too much capital or earns weaker incremental returns.
3. Management capital allocation becomes value-destructive or evasive, as in the Unilever/GSK critique and the PayPal concerns around engagement, cost control, acquisitions, and incentives (Unilever/GSK post mortem, 2022; Fundsmith 2022 annual letter).
4. Valuation leaves inadequate forward free-cash-flow return, as shown by the Domino's sales and later regret (Fundsmith 2015 annual letter; Fundsmith 2016 annual letter).
5. A superior candidate offers better quality-adjusted compounding within the concentrated portfolio.

The hard part is timing. Morningstar's 2024 downgrade argued that Fundsmith had both sold some winners too early and exited some losers too late, which means the sell model is the most fragile part of an otherwise clear process (Morningstar downgrade, 2024).

Risk limits

The product-level risk limits are unusually plain: no shorting, no derivatives as a return tool, no currency hedging, no securities financing transactions, no total-return swaps, no fund-of-funds exposure, no market timing, and temporary borrowing only as a limited UCITS tool capped at 10% of scheme property (Fundsmith prospectus, 2026; Fundsmith June factsheet, 2026). The investment-level risk limits are also simple: avoid leverage-dependent businesses, avoid weak cash conversion, avoid capital intensity that destroys incremental returns, and avoid structures where client liquidity and portfolio liquidity do not match.

Failure modes of the model

Quality at any price

The model can overvalue durability. If the analyst assumes the franchise will last indefinitely, almost any price can appear acceptable. Fundsmith tries to fight this with free-cash-flow yield, but the recent underperformance shows that valuation discipline remains vulnerable when rates rise or when expensive quality stocks de-rate. Morningstar's 2024 critique raised uncertainty around valuation and free-cash-flow-yield support even while it continued to respect the process (Morningstar downgrade, 2024).

Do nothing becomes stale-thesis inertia

Inactivity is valuable only if the original thesis remains valid. PayPal is the warning case: Fundsmith enjoyed several years of strong contributions after the eBay spin, then the stock became a material detractor as Smith criticized engagement, cost control, acquisitions, and incentive design (Fundsmith 2017 annual letter; Fundsmith 2022 annual letter). Trustnet's Smithson interview is not direct Terry Smith flagship evidence, but it supports the same failure mode: Fundsmith-aligned managers said turnover and transaction-cost concerns contributed to keeping some holdings they probably should have sold (Trustnet Smithson interview, 2023).

Accounting quality does not immunize against strategic change

Clean accounts can coexist with business risk. Novo Nordisk had been an archetypal quality holding, but it detracted 3.0% in 2025 as Smith cited execution, management, and competitive pressures, while the 2025 semiannual letter said Novo and Coloplast more than accounted for all first-half underperformance (Fundsmith 2025 annual letter, 2026; Fundsmith 2025 semiannual letter). The lesson is that cash-return evidence is backward-looking unless paired with a live view of competition, regulation, supply constraints, and management execution.

Benchmark independence can become multi-year relative pain

The flagship's June 2026 factsheet shows underperformance versus MSCI World in 2022, 2023, 2024, 2025, and year-to-date through 30 June 2026: -13.8% versus -7.8%, +12.4% versus +16.8%, +8.9% versus +20.8%, +0.8% versus +12.8%, and -2.9% versus +11.2% (Fundsmith June factsheet, 2026). Smith's passive-flow and AI-concentration explanation is plausible, but the mental-model risk is obvious: being fundamentally disciplined can still lose to benchmark mechanics for years.

The AI capex question attacks the asset-light premise

Fundsmith's owned technology winners became harder to underwrite when AI spending rose. The 2024 letter flagged higher capital expenditure at Alphabet, Microsoft, Meta, and Novo Nordisk and asked whether the AI arms race would earn adequate returns (Fundsmith 2024 annual letter, 2025). This is a direct challenge to the intangible-franchise model: a software or platform business may stop behaving like an asset-light compounder if competitive pressure forces continuous heavy infrastructure investment.

Vehicle fit is not guaranteed

Fundsmith Emerging Equities Trust shows that the flagship model does not transfer automatically to other universes. Trustnet reported that FEET rose only 22.3% from launch, trailing peers and MSCI Emerging Markets, and the trust was liquidated after returns fell below expectations; the final report records GBP337.9 million distributed in a members' voluntary liquidation, not a creditor insolvency (Trustnet FEET article, 2022; FEET final report, 2025; Companies House FEET insolvency record).

Smithson adds a second vehicle lesson. The 2025 report showed NAV total return of -1.8% for the year versus +10.2% for the SMID comparator and +60.2% since listing versus +80.9% for the comparator; the board later proposed an OEIC reconstruction after persistent discount pressure (Smithson 2025 report; Smithson restructure proposal). The same quality language did not solve small/mid-cap liquidity, discount, and governance pressure.

Key-person and organizational risk

Morningstar's 2026 review still retained a favorable rating but highlighted one-, three-, and five-year underperformance, stock-specific upsets, narrow market leadership, and key-person/internal-challenge risk (Morningstar 2026 review; Fundsmith-hosted Morningstar report, 2026). A simple process can still depend heavily on judgment: when to treat a drawdown as a glitch, when to accept benchmark pain, when to trim a winner, and when to admit quality has eroded.

Transferability

What an individual investor can replicate

An individual investor can copy the checklist more easily than the institution. The practical version is:

1. Start with business quality, not price charts: require high returns on operating capital, strong margins, cash conversion, low financial leverage, and evidence of durable franchise assets.
2. Read primary filings and annual reports before commentary, then reconcile management's story with cash flow, capital employed, debt, leases, stock compensation, acquisition accounting, and recurring adjustments.
3. Use free-cash-flow yield and reinvestment runway as the valuation anchor, not a single P/E multiple.
4. Maintain a short watchlist of businesses good enough to own for years, and demand a written reason before adding a mediocre business just because it looks cheap.
5. Keep turnover low, but review explicit sell triggers annually: quality decay, worse incremental returns, poor capital allocation, valuation excess, or a superior candidate.
6. Avoid complexity that is unnecessary for compounding: leverage, derivatives, market timing, currency calls, and portfolio activity done mainly to feel useful.
7. Track language. If management relies on buzzwords, adjusted metrics, or evasive strategy language, force the thesis back to cash returns and capital allocation.

The mental model is especially transferable because it is mostly public-information based. Smith's accounting essays, annual letters, factsheets, and SEC filings show a process that individuals can approximate with company reports, filings, and patience. The challenge is not access to exotic data; it is consistency under underperformance.

What an individual investor cannot fully replicate

Several parts of Fundsmith's implementation are not easily copied. Individual investors do not have the same research team, internal models, management access, portfolio analytics, execution infrastructure, tax wrappers, daily liquidity systems, compliance apparatus, or ability to absorb large redemptions without disrupting the portfolio. They also do not have Fundsmith's brand, client communication machinery, or institutional tolerance for holding 20-30 global names at large scale.

The exact sizing method is not disclosed. Investors can copy the principle of concentration, but not the internal risk scoring, trading constraints, liquidity analysis, or client-flow management that support a GBP12.3 billion open-ended fund with 31 holdings and 93% seven-day liquidity (Fundsmith June factsheet, 2026). They should also avoid overreading 13F filings: those filings are U.S. long-position snapshots, not full global ledgers, and the SEC warns that they should not be assumed complete or accurate for all analytical purposes (SEC 13F FAQ; SEC Fundsmith LLP 13F Q1 2026).

Finally, individuals cannot outsource temperament by adopting the slogan. Fundsmith's recent five-year lag shows that even a clear process can be hard to hold when clients, ratings firms, headlines, and benchmarks punish difference. A private investor copying Smith needs a personal version of the Owner's Manual: what will be owned, what will be excluded, what price discipline will be used, what evidence will trigger sale, and how long relative underperformance can be tolerated before the thesis is re-tested.

Best individual adaptation

The most robust adaptation is a smaller, written quality-compounding process: 15-25 companies or funds rather than 30-plus single stocks if the investor lacks time; no leverage; documented cash-return and moat tests; explicit valuation ranges based on free cash flow; annual sell-rule reviews; and a log of accounting red flags. The investor should copy Smith's habits, not his holdings mechanically. The habits are durable: distrust cosmetic earnings, prefer high cash returns, avoid leverage-dependent economics, let compounding work, and be honest when "do nothing" becomes an excuse for not thinking.

As of: 2026-07-03T19:43:21Z

Evidence note

This synthesis is based on completed Terry Smith Canon files A, B, C, F, and G plus fresh checks of current Fundsmith, SEC, Morningstar, Smithson, FEET, and criticism sources. Tasks D and E were still claimed and unavailable when this H task closed, so the synthesis explicitly preserves a refresh dependency for a future mistakes file and direct quote file.

Executive brief

Terry Smith is the modern public-fund expression of a very old investing idea: own superior businesses long enough for high returns on capital to compound. What makes him distinctive is not the quality-growth label by itself. It is the accounting-forensic origin of the method. Smith first became famous for Accounting for Growth, a critique of reported-profit illusion, and Fundsmith later turned the negative habit of spotting accounting camouflage into a positive screen for companies whose cash economics are unusually clean (Fundsmith/FT accounting essay; Internet Archive catalog).

The core doctrine is compact: buy good companies, do not overpay, and do nothing. In practice, "good" means high cash returns on operating capital, strong cash conversion, low leverage, durable intangible assets, resilience to change, and a reinvestment runway; "do not overpay" is anchored in free-cash-flow yield and durability rather than a simple P/E rule; and "do nothing" is a promise to avoid frictional trading when the business thesis remains intact (Fundsmith Owner's Manual; Fundsmith 2025 annual letter).

The verified flagship record is strong but no longer uncomplicated. Fundsmith Equity Fund T Accumulation shares returned +592.6% cumulative and +13.1% annualized from 1 November 2010 to 30 June 2026, compared with MSCI World GBP net +530.9% and +12.5%. The same June 2026 factsheet shows a difficult second chapter: -2.9% year to date in 2026 versus +11.2% for the comparator, +0.8% in 2025 versus +12.8%, and a fund size of GBP12.3 billion with 31 holdings and 7.0% cash (Fundsmith June 2026 factsheet). The live factsheet page also showed price data dated 3 July 2026 and a top-ten list led by Marriott, Waters, Stryker, L'Oreal, Amadeus, Visa, Philip Morris, Fortinet, ADP, and Church & Dwight (Fundsmith factsheet page).

Smith's best evidence is Microsoft, Meta, IDEXX, Stryker, Philip Morris, and Domino's: long-term public equities where a high-return business, bought during skepticism or held through controversy, did the heavy lifting. Microsoft is the clearest best trade, but even that winner had to be trimmed when AI capital spending threatened the asset-light economics Fundsmith prefers (Terry Smith greatest-trades file; Interactive Investor, 2026). The same pattern has produced mixed cases: PayPal generated large early contribution before becoming a sell-discipline warning, and Novo Nordisk moved from archetypal quality winner to live risk case as competition, execution, and management issues surfaced (Fundsmith 2022 annual letter; Fundsmith 2025 annual letter).

The honest synthesis is that Smith is a highly teachable quality-compounding investor whose method is easier to state than to execute. The transferable lessons are powerful: read the accounts, prefer cash returns, avoid leverage-dependent businesses, let compounding work, and write down the sell triggers before the crisis. The non-transferable parts are just as important: Fundsmith's research team, open-ended vehicle plumbing, brand, client communication machine, liquidity management, and founder-dependent judgment. Independent critics have not disproved the philosophy, but they have identified the central execution risk: distinguishing temporary share-price pain from permanent business-quality decay (Morningstar downgrade, 2024; Morningstar review, 2026).

10 transferable lessons, ranked

1. Start with cash returns on real operating capital. Smith's most useful rule is to distrust reported EPS until it has been reconciled to cash generation, return on capital, debt, leases, recurring adjustments, and stock compensation. Tesco, AstraZeneca, and Intuit show why reported growth without cash-return discipline can be misleading (Tesco essay; AstraZeneca essay; Fundsmith 2022 annual letter).

2. Make the negative screens explicit before valuation seduces you. Smith avoids banks and other leverage-dependent businesses because adequate equity returns can depend on fragile balance-sheet gearing. For individual investors, the lesson is to reject some categories before asking whether the price is cheap (bank shares essay, 2023; Fundsmith Owner's Manual).

3. Prefer intangible durability only when the cash confirms it. Brands, installed bases, distribution systems, patents, and customer relationships matter because they can prevent mean reversion in returns, not because "moat" is a pretty word. Smith's process ties intangible advantage back to observed margins, cash conversion, and reinvestment runway (Owner's Manual; Fundsmith 2025 annual letter).

4. Low turnover is an output, not a virtue by itself. Microsoft, Stryker, IDEXX, Meta, and Philip Morris rewarded long holding periods; PayPal and Novo show why inaction must still be periodically re-underwritten. "Do nothing" works only while the original economics remain intact (greatest-trades file; Morningstar downgrade).

5. Use free-cash-flow yield as a valuation anchor, but do not let duration become a blank cheque. Fundsmith compares portfolio free-cash-flow yield with market yields, but the post-2021 lag shows that quality can still de-rate when rates rise or when the market changes the required return (Fundsmith 2025 annual letter; Morningstar 2026 review).

6. Treat sell discipline as the hardest part of quality investing. A value investor often has an obvious sell trigger when price meets value; a quality investor's trigger is fuzzier because good businesses can look temporarily impaired. Fundsmith's late exits from PayPal and Estee Lauder and early exits from Amazon and Adobe are the central critique to study (Morningstar downgrade; Guardian coverage).

7. Benchmark independence is necessary but expensive. Fundsmith's 88% active share and concentrated holdings make the fund genuinely different from the index, but the recent narrow, AI-led market shows that being different can mean multi-year relative pain (Fundsmith June 2026 factsheet; Fundsmith 2025 annual letter).

8. Vehicle fit matters as much as philosophy. FEET and Smithson show that quality screens do not automatically travel into every geography, capitalization band, or wrapper. Emerging markets, small/mid caps, closed-end discounts, buybacks, Saba pressure, tax frictions, and liquidity structure all became part of the result (FEET final report; Trustnet FEET article; Smithson 2025 report; AJ Bell Smithson analysis).

9. Do not clone 13F filings as a portfolio map. Fundsmith's Q1 2026 13F reported 34 entries and USD12.83 billion of reportable value, but it excludes many non-U.S. holdings, cash, exact trade timing, cost basis, and full fund exposure. It is a useful clue, not a ledger (SEC Q1 2026 13F cover; SEC Q1 2026 13F table; SEC 13F FAQ).

10. Write your own Owner's Manual. The most transferable Fundsmith artifact is not the holding list; it is the pre-commitment document. Individual investors need a written version of what they will own, what they will reject, how they value, when they sell, and how long they can tolerate looking wrong (Owner's Manual).

Style taxonomy tags

• Quality growth
• Accounting forensics
• Cash-ROCE / cash-conversion discipline
• High-ROCE intangible franchises
• Concentrated global long-only equities
• Low turnover / patient compounding
• Free-cash-flow-yield valuation anchor
• Negative screens for leverage-dependent economics
• Public active fund / daily-dealing OEIC
• Active-share and key-person risk
• Style-cycle and sell-discipline risk
• Vehicle-transferability risk

Regime dependence

Smith's flagship works best in regimes where durable, asset-light, high-return businesses can reinvest at attractive incremental returns and markets are willing to pay for multi-year cash compounding. The 2010-2021 period was close to ideal: low rates supported long-duration equities, global quality franchises outperformed, and Fundsmith's refusal to trade looked like discipline rather than stubbornness. The December 2021 factsheet showed +570.7% since inception and +18.6% annualized, with the flagship at GBP28.9 billion (Fundsmith December 2021 factsheet).

The strategy struggles when market leadership narrows into stocks the process cannot or will not own at benchmark weight, or when rising rates compress long-duration quality valuations. Fundsmith's own 2022 letter emphasized rate pressure on growth equities, while the 2024 and 2025 letters emphasized AI, Nvidia, index concentration, passive flows, and dollar weakness as drivers of relative pain (Fundsmith 2022 annual letter; Fundsmith 2024 annual letter; Fundsmith 2025 annual letter). UBS's 2026 market commentary also supports the broad point that the top ten U.S. market names were near 40% of the S&P 500, making concentration a real benchmark issue, though it does not validate every Fundsmith stock decision (UBS, 2026).

AI is the current stress test because it challenges both sides of Smith's model. On one hand, the market may be rewarding a genuine technology transition. On the other, Smith's concern is that transformative technology does not guarantee adequate returns to the companies spending the capital. If Microsoft, Meta, Alphabet, or other platform businesses become permanently more capital intensive, they may no longer fit the clean asset-light compounder template that made them attractive (Fundsmith 2024 annual letter; Interactive Investor, 2026).

The vehicle regime is also crucial. A daily-dealing UK OEIC holding large public equities can survive redemptions if portfolio liquidity remains high; the June 2026 factsheet reported 93% seven-day liquidity. That does not mean client behavior is irrelevant. Financial News reported heavy recent outflows, including GBP3.3 billion in 2024 and later visible headlines about further outflows in 2025 and Q1 2026; those reports are secondary and partly paywalled, but they capture the reputational and flow pressure that an open-ended public fund faces during multi-year underperformance (Fundsmith June 2026 factsheet; Financial News 2024 outflow report; Financial News 2025 outflow headline; Financial News 2026 outflow headline).

Closest and most-opposite investors already in repo

Closest: Philip Fisher. Fisher is the closest Canon analogue because both investors seek superior companies with long growth runways, management quality, concentrated ownership, and patience. The difference is evidence style: Fisher's edge was scuttlebutt and qualitative company research, while Smith is more accounting-led, cash-return-led, and explicit about negative sector screens.

Also close: Charlie Munger and Warren Buffett. Smith sits in the Buffett-Munger lineage of business quality, moats, low activity, and owner-level thinking. The structural difference is large: Buffett and Munger had Berkshire's float, tax deferral, operating-company control, and permanent capital; Smith runs a public daily-dealing fund where benchmark comparison and redemptions are part of the operating environment.

Also close: Li Lu. Li Lu and Smith are both concentrated, patient, Buffett-Munger-descended quality investors who warn against blind cloning. Li Lu's edge is private partnership structure and China/Asia local knowledge; Smith's edge is a global developed-market quality filter rooted in accounting skepticism and explicit sector exclusion.

Most opposite: Jack Bogle. Bogle is the philosophical opposite because he argued that broad, low-cost market ownership is the rational default when active edge is rare. Smith argues that a concentrated active portfolio can win by owning exceptional companies after fees. The nuance is that both dislike unnecessary trading and cost; they simply draw opposite conclusions from that arithmetic.

Most opposite within active equity: Bill Miller. Miller stretched value investing into expectations, controversy, optionality, financials, and later Bitcoin. Smith excludes many fragile, leveraged, or uncertain business models before valuation begins. Miller's favorable regime is pessimism around misunderstood optionality; Smith's is underappreciated duration in clean cash economics.

Useful foil: Howard Marks. Marks shares price/value discipline and humility about forecasting, but his opportunity set is credit, distress, cycles, terms, covenants, and forced sellers. Smith's is high-ROCE listed equity compounders where doing nothing is meant to be the default.

Luck vs skill

The skill component is substantial. Fundsmith's early Microsoft purchase, IDEXX scale, long Stryker holding, and avoidance of leverage-dependent sectors were not random. They followed a repeatable doctrine: find durable cash-return economics, own concentrated stakes, communicate the process, and keep costs and turnover low. The firm also built a retail-facing product whose simplicity made it unusually legible compared with many active funds (Fundsmith June 2026 factsheet; Fundsmith Owner's Manual).

The luck and path-dependence are also real. The first decade benefited from a favorable quality-growth regime and low-rate environment. Some early sales and holds look better or worse depending on what happened after the decision, and the absence of a public trade ledger prevents precise P&L attribution. The flagship's since-inception lead over MSCI World remains intact as of 30 June 2026, but the lead has narrowed, and the post-2021 record is a live test rather than a closed proof (Fundsmith June 2026 factsheet; Morningstar 2026 review).

Unresolved questions

• Refresh this synthesis after T0303 D-mistakes and T0304 E-own-words close. The current file already incorporates known mistakes and quote caveats from A/B/C/F/G, but those tasks should add sharper failure cases and verified direct language.
• Page-check Accounting for Growth and the 2020/2026 editions of Investing for Growth against physical or authorized copies before using chapter-level claims or exact quotations beyond catalog metadata (Internet Archive; Harriman House).
• Reconstruct a full month-by-month or quarter-by-quarter Fundsmith AUM history. Current observed points include flagship GBP28.9 billion at 31 December 2021, firmwide GBP34 billion at 31 December 2024, firmwide GBP24 billion at 31 December 2025, and flagship GBP12.3 billion at 30 June 2026 (Fundsmith December 2021 factsheet; Fundsmith global site; Fundsmith June 2026 factsheet).
• Separate Terry Smith's direct portfolio-manager decisions from broader Fundsmith franchise outcomes, especially FEET after Smith's direct PM role ended and Smithson's day-to-day small/mid-cap management (Smithson 2025 report; FEET final report).
• Verify any official FCA Register or Section 166 documentation in a browser or source that renders cleanly. Current evidence relies on Fundsmith regulatory footers, Companies House, SEC filings, Portfolio Adviser, Financial News, and the FCA's generic skilled-person-review page rather than an FCA firm-specific final notice (FCA skilled persons reviews; Portfolio Adviser 2022).

Started for Task A-profile on 2026-07-03T14:04:54Z.

Ranked source map

1. Fundsmith global site - Best current first-party source for firmwide FUM, eight-fund product map, UK/Mauritius/USA affiliate structure, Smith's CEO/CIO role, and official biography.
2. Fundsmith Equity Fund factsheet, June 2026 - Current first-party source for Terry Smith as portfolio manager, fund size, holdings count, inception date, fees, investment criteria, current performance, recent annual returns, and regulatory footer.
3. Fundsmith Equity Fund 2025 annual letter - Best source for 2025 underperformance, since-inception table to 31 December 2025, Smith's explanation of index concentration/passive flows/currency, and stock-level commentary.
4. Fundsmith Equity Fund Owner's Manual, 2025 - Core source for investment philosophy, official biography, "good companies/don't overpay/do nothing" framing, and firm FUM/product list as of 31 December 2024.
5. Fundsmith Equity Fund prospectus, March 2026 - Primary legal/product document for the UK OEIC, ACD/investment-manager roles, risks, investment powers, and FCA/UCITS framework.
6. Fundsmith Equity Fund factsheet, December 2021 - Best observed official high-water source for flagship fund size (£28.9bn) and pre-underperformance long-term record (+570.7% since inception, +18.6% annualised).
7. Companies House Fundsmith LLP overview - Primary UK corporate source for incorporation date, active status, registered office, prior name, and account/confirmation-statement dates.
8. Companies House Fundsmith LLP PSC page - Primary source for Terence Charles Smith's month/year of birth, British nationality, Mauritius residence, and controlling rights in the LLP.
9. Fundsmith LLP 13F cover page, Q1 2026 - Primary SEC filing for U.S.-reportable holdings count/value, CRD/SEC identifiers, filing date, and 13F caveat.
10. Fundsmith Equity Fund LP Form D/A, 2024 - Primary U.S. private-fund source for Delaware LP structure, Rule 506(b), Section 3(c)(7), minimum investment, amount sold, and investor count.
11. Smithson Investment Trust 2025 report - Best current source for Smithson performance, discount, buybacks, proposed OEIC conversion, and small/mid-cap Fundsmith-style approach.
12. Smithson restructuring circular, 2026 - Primary source for the trust-to-OEIC reconstruction rationale, shareholder options, relative performance, and discount-management context.
13. Fundsmith Emerging Equities Trust final liquidators' report - Primary liquidation source for members' voluntary liquidation, distributions, tax loose ends, and closure mechanics.
14. Trustnet: Fundsmith liquidates Emerging Equities Trust after poor performance - Useful secondary context for why FEET was wound up and how investors/industry observers interpreted the closure.
15. Morningstar: Fundsmith Equity Fund Retains Appeal for Long-Term Investors, June 2026 - Independent current assessment balancing long-term strengths with underperformance, key-person risk, bench depth, and sell-discipline concerns.
16. Morningstar: Fundsmith Equity downgraded from Gold to Silver, March 2024 - Original ratings-agency explanation of the downgrade and core critique of sell discipline.
17. Guardian report on Morningstar downgrade, March 2024 - Secondary but accessible report tying downgrade, missteps, profits, withdrawals, and Fundsmith's response together.
18. Financial News: FCA orders Fundsmith review, May 2022 - Media source for Section 166 review context; use with caveat because official FCA page did not render in this environment.
19. Portfolio Adviser: Fundsmith handed clean sheet after Section 166 review, July 2022 - Follow-up context saying recommendations were made but no further action was required; use as secondary reporting, not an FCA final notice.
20. DPMC New Year Honours List 2012 - Official source for Smith's appointment as MNZM for services to New Zealand-United Kingdom relations.
21. Fundsmith documents hub - First-party index for annual letters, owners' manuals, reports, prospectuses, and future Task B-H source collection.
22. FCA Register page for Fundsmith LLP - Official target for FCA status verification, but it rendered a CSS/JavaScript error during this run; revisit in a browser that can load it.
23. Fundsmith Mauritius site - First-party source for Mauritius affiliate licensing context and Fundsmith Global Equity Fund Feeder details.
24. Financial News outflow reporting, 2025 - Useful but paywalled/secondary source for outflow and shrinking-asset context; triangulate against accounts or Morningstar Direct before hard use.
25. Pan Macmillan author page for Terry Smith - Publisher biography for book/career context; useful as corroboration but weaker than Fundsmith's own biography and corporate filings.

Task A caveats

• Companies House gives only month/year of birth, not a complete date. Do not treat the commonly cited day of birth as primary-sourced until verified.
• The flagship track record is a share-class fund return, net of fees. It is not Smith's personal return and not a composite of all Fundsmith products.
• Fundsmith's MSCI World figures are informational comparators; the fund states it is not managed by reference to a benchmark.
• 13F value is not full AUM, full exposure, or performance evidence.
• Form D "amount sold" is offering history, not current fund NAV.
• FCA Register did not render usable content during this run; Fundsmith's regulatory footer and official filings were used instead.
• Smithson and FEET belong in the franchise record, but future tasks should separate Smith's direct PM decisions from CIO oversight and other portfolio managers' day-to-day responsibility.

T0301 - B-philosophy sources (2026-07-03T14:41:08Z)

1. Fundsmith Equity Fund Owner's Manual 2025 - primary doctrine for the three-part slogan, high-ROCE/cash/intangible/franchise criteria, anti-benchmark posture, no greater-fool theory, no market timing, and investor temperament. https://www.fundsmith.co.uk/media/mv3abv1h/fef-owners-manual-a4-2025.pdf
2. Fundsmith Equity Fund Prospectus 2026 - primary legal source for mandate, UCITS/OEIC structure, 20-30 stock expectation, diversification rules, borrowing limits, no derivatives, no hedging, no securities financing, and fee structure. https://www.fundsmith.co.uk/media/5gtnxzgh/fundsmith-equity-fund-prospectus-2026.pdf
3. Fundsmith Equity Fund June 2026 factsheet - primary current snapshot for holdings count, cash, active share, performance, and stated investment policy. https://www.fundsmith.co.uk/media/b22dtyny/june.pdf
4. Fundsmith 2025 annual letter, dated January 2026 - primary source for 2025 underperformance framing, index concentration/passive-flow critique, AI-capex return skepticism, turnover, and Brown-Forman/PepsiCo/Intuit sell-discipline examples. https://www.fundsmith.co.uk/media/4hcfd1pg/2025-fef-annual-letter-web.pdf
5. Fundsmith 2024 annual letter, dated January 2025 - primary source for Nvidia/AI valuation framing, 2024 underperformance, detractors, FCF-yield comparison, and turnover. https://www.fundsmith.co.uk/media/pirmvyly/annual-letter-to-shareholders-2024.pdf
6. Fundsmith 2024 semiannual letter - primary source for narrow S&P 500 return attribution and Nvidia concentration in H1 2024. https://www.fundsmith.co.uk/media/uznnt5w2/2024-fef-semi-annual-letter-to-shareholders.pdf
7. Fundsmith 2023 annual letter - primary source for Magnificent Seven concentration discussion and benchmark-weight resistance. https://www.fundsmith.co.uk/media/31plodnq/2023-fef-annual-letter-to-shareholders.pdf
8. Fundsmith 2022 annual letter - primary source for rising-rate/long-duration underperformance explanation and detractor context. https://www.fundsmith.co.uk/media/bm0lyc22/annual-letter-to-shareholders-2022.pdf
9. Fundsmith short-form report 2024 - primary source for look-through quality metrics: ROCE, margins, cash conversion, interest cover. https://www.fundsmith.co.uk/media/2l1p53ou/2024-short-form-report-for-the-twelve-months-ended-31-december-2024.pdf
10. Fundsmith short-form report 2022 - primary source for Intuit/share-based-compensation free-cash-flow adjustment. https://www.fundsmith.co.uk/media/y3ll0d4j/2022-short-form-report-for-the-twelve-months-ended-31-december-2022.pdf
11. Fundsmith/Financial Times article by Smith, 2015, "Why bother cooking the books if no one reads them?" - first-person retrospective on Accounting for Growth and accounting trickery. https://www.fundsmith.co.uk/news/2015/2081-financial-times-why-bother-cooking-the-books-if-no-one-reads-them/
12. FT Adviser profile, 2022 - secondary source on Accounting for Growth origin, UBS reaction, and Smith biography. https://www.ftadviser.com/content/c5b71ba1-b60d-5d4b-aa75-d66e36575f9f
13. Pan Macmillan Terry Smith author biography - publisher corroboration for UBS head-of-research role and dismissal after Accounting for Growth. https://www.panmacmillan.com/authors/terry-smith/48467
14. Internet Archive metadata for Accounting for Growth - bibliographic source for 1996 second edition, earlier 1992 edition, and description; access-restricted, not treated as read full text. https://archive.org/details/accountingforgro0000smit_y4v0
15. Google Books metadata for Accounting for Growth - bibliographic/source-topic support for accounting issues covered in the book; metadata only. https://books.google.com/books/about/Accounting_for_Growth.html?id=wp3WrQEACAAJ
16. Smith article, "Why I never invest in bank shares," 2023 - primary source for anti-bank/leverage logic and NatWest example. https://www.fundsmith.co.uk/news/2023/4933-financial-times-why-i-never-invest-in-bank-shares/
17. Smith article on Tesco, 2014 - primary source for EPS-versus-ROCE/cash-flow accounting skepticism. https://www.fundsmith.co.uk/news/2014/2050-financial-times-how-investors-ignored-the-warning-signs-at-tesco/
18. Smith article on AstraZeneca/Tesco, 2017 - primary source for critique of adjusted/core earnings and return-on-capital deterioration. https://www.fundsmith.co.uk/news/2017/2038-financial-times-astrazeneca-is-beginning-to-look-like-tesco/
19. Richer, Wiser, Happier transcript, 2025 - first-person interview transcript on reading accounts, economic reality, ROCE, cash conversion, and competitive advantage; transcript quality caveat. https://www.theinvestorspodcast.com/richer-wiser-happier/billionaire-brit-w-terry-smith/
20. The Market/NZZ interview republished by Fundsmith, 2024 - current articulation of quality, reinvestment, predictability, capital allocation, valuation, and excluded sectors. https://www.fundsmith.co.uk/news/2024/5553-5553-the-market-nzz-valuation-is-not-as-important-as-quality/
21. Morningstar downgrade, 2024 - independent critique focused on sell discipline and timing of Amazon/Adobe/PayPal/Estee Lauder decisions. https://global.morningstar.com/en-gb/funds/morningstar-downgrades-fundsmith-equity-from-gold-to-silver
22. Morningstar review, 2026 - independent update retaining Silver rating while noting 1/3/5-year underperformance and regime context. https://global.morningstar.com/en-gb/funds/fundsmith-equity-fund-retains-appeal-long-term-investors
23. The Guardian, 2024, Morningstar downgrade coverage - secondary reputational/outflow/pay context; mostly downstream from Morningstar. https://www.theguardian.com/business/2024/mar/28/stock-picker-terry-smith-fundsmith-equity-downgraded-by-ratings-firm-share-sales
24. Portfolio Adviser, 2025 - secondary source on fourth year of underperformance and Diageo sale context. https://portfolio-adviser.com/terry-smith-defends-fundsmith-equity-record-after-fourth-year-of-underperformance/
25. Trustnet, 2025, buy/hold/fold - secondary source for investor-flow and quartile-performance context. https://www.trustnet.com/news/13435606/should-you-buy-hold-or-fold-fundsmith-equity
26. Trustnet, 2025, IA Global flows - secondary source for reported 2024 Fundsmith Equity net outflows and AUM movement. https://www.trustnet.com/news/13437291/the-most-bought-and-sold-ia-global-funds-of-last-year
27. Trustnet, 2022, FEET liquidation - secondary source on emerging-equities trust liquidation after poor performance and Smith's stated fee/capital rationale. https://www.trustnet.com/news/13328539/fundsmith-liquidates-emerging-equities-trust-after-poor-performance
28. Fundsmith Emerging Equities Trust final report, 2025 - primary source for liquidation distributions and overseas tax/settlement friction. https://www.fundsmith.co.uk/media/i5qnbwzt/feet-final-report.pdf
29. Smithson Investment Trust 2025 report - primary source for small/mid-cap strategy, performance, and vehicle context. https://www.smithson.co.uk/media/laslz1yj/report-for-the-year-ended-31-december-2025.pdf
30. Smithson restructuring RNS, 2025 - primary source for proposed OEIC rollover, persistent discount, buybacks, and relative underperformance since early 2022. https://www.investegate.co.uk/announcement/rns/smithson-investment-trust--sson/restructure-proposals/9227742
31. AJ Bell Smithson analysis, 2025 - secondary critique of Smithson restructuring and Saba context. https://www.ajbell.co.uk/group/news/terry-smith-sides-activist-investor-saba-major-changes-proposed-smithson-investment-trust
32. Trustnet Smithson interview, 2023 - secondary source with managers' admission that turnover/transaction-costs considerations contributed to keeping some stocks too long. https://www.trustnet.com/news/13394301/smithson-turnover-and-transaction-costs-factored-into-us-keeping-stocks-we-probably-should-have-sold
33. Fundsmith LLP 13F, Q1 2026 - official SEC snapshot of reportable US long holdings; incomplete for total exposure. https://www.sec.gov/Archives/edgar/data/1569205/000156920526000005/xslForm13F_X02/primary_doc.xml
34. Fundsmith Equity Fund L.P. Form D/A, 2024 - official SEC source for US private fund offering metadata; not a portfolio-policy source. https://www.sec.gov/Archives/edgar/data/1520023/000089843224000750/xslFormDX01/primary_doc.xml
35. Companies House Fundsmith LLP page - official legal-entity corroboration for Fundsmith LLP. https://find-and-update.company-information.service.gov.uk/company/OC354233

T0302 - C-greatest-trades sources (2026-07-03T16:33:10Z)

1. Fundsmith Equity Fund 2025 annual letter - primary source for 2025 performance, Novo -3.0 detractor, Alphabet/IDEXX/Philip Morris/Meta/Microsoft top contributors, and Microsoft/Meta repeat-contributor counts. https://www.fundsmith.co.uk/media/4hcfd1pg/2025-fef-annual-letter-web.pdf
2. Fundsmith Equity Fund 2024 annual letter - primary source for 2024 detractors/contributors, Microsoft price/update, Meta/Microsoft repeat-contributor framing, Philip Morris RRP discussion, Stryker elective-surgery backlog, IDEXX and Novo caveats. https://www.fundsmith.co.uk/media/pirmvyly/fundsmith-annual-letter-to-shareholders-2024.pdf
3. Fundsmith Equity Fund 2023 annual letter - primary source for Meta +4.5, Microsoft +3.9, Novo +3.6, L'Oreal +2.1, IDEXX +1.4, and Microsoft/Novo commentary. https://www.fundsmith.co.uk/media/31plodnq/2023-fef-annual-letter-to-shareholders.pdf
4. Fundsmith Equity Fund 2022 annual letter - primary source for rising-rate drawdown context, Microsoft/Novo/Philip Morris/PayPal/Intuit commentary, and 2022 sale examples. https://www.fundsmith.co.uk/media/bm0lyc22/annual-letter-to-shareholders-2022.pdf
5. Fundsmith Equity Fund 2021 annual letter - primary source for Microsoft +3.9, Intuit +3.1, Novo +2.3, IDEXX +1.9 and quality-growth drawdown context. https://www.fundsmith.co.uk/media/3wcngjie/2021-fef-annual-letter-to-shareholders-web.pdf
6. Fundsmith Equity Fund 2020 annual letter - primary source for PayPal +5.1, IDEXX +3.1, Microsoft +2.8, Intuit +1.5, Meta/Facebook +1.4 and Covid-era context. https://www.fundsmith.co.uk/media/deujnq00/annual-letter-to-shareholders-2020.pdf
7. Fundsmith Equity Fund 2019 annual letter - primary source for Microsoft, Meta/Facebook, PayPal and Philip Morris contribution evidence. https://www.fundsmith.co.uk/media/hoeistqg/annual-letter-to-shareholders-2019.pdf
8. Fundsmith Equity Fund 2018 annual letter - primary source for IDEXX/Intuit top-contributor evidence and Meta/Facebook/Philip Morris drawdown evidence. https://www.fundsmith.co.uk/media/sulfjbdr/annual-letter-to-shareholders-2018.pdf
9. Fundsmith Equity Fund 2017 annual letter - primary source for Novo and PayPal contribution evidence. https://www.fundsmith.co.uk/media/ceadumtv/annual-letter-to-shareholders-2017.pdf
10. Fundsmith Equity Fund 2016 annual letter - primary source for IDEXX, Stryker, and Novo early evidence. https://www.fundsmith.co.uk/media/wmul2sfh/2016-annual-letter-to-shareholders.pdf
11. Fundsmith Equity Fund 2015 annual letter - primary source for Domino's best-performing-share language and sale context. https://www.fundsmith.co.uk/media/5jgdehk1/annual-letter-to-shareholders-2015.pdf
12. Fundsmith Equity Fund 2014 annual letter - primary source for Microsoft, Stryker, Domino's, and Dr Pepper early top-contributor evidence. https://www.fundsmith.co.uk/media/wiulqdhi/annual-letter-to-shareholders-2014.pdf
13. Fundsmith Equity Fund 2013 annual letter - primary source for Microsoft, Stryker, Domino's and early attribution figures. https://www.fundsmith.co.uk/media/r42lzm0b/annual-letter-to-shareholders-2013-pdf.pdf
14. Fundsmith Equity Fund 2011 annual letter - primary source for early Stryker, Philip Morris and Domino's context. https://www.fundsmith.co.uk/media/khugzwcd/annual-letter-to-shareholders-2011-pdf.pdf
15. Fundsmith Equity Fund 2010 annual letter - primary source for earliest Domino's and initial portfolio context. https://www.fundsmith.co.uk/media/2iiacacc/annual-letter-to-shareholders-2010-pdf.pdf
16. Fundsmith 2025 short-form report - primary source for large 2025 sale proceeds including Meta, Microsoft and Philip Morris; also used for 2024 comparative sale proceeds including Novo. https://www.fundsmith.co.uk/media/uxvf5sjz/2025-short-form-report-for-the-twelve-months-ended-31-december-2025.pdf
17. Fundsmith 2023 short-form report - primary source for IDEXX purchase/sale data and annual report context. https://www.fundsmith.co.uk/media/4iwlhlg0/2023-short-form-report-for-the-twelve-months-ended-31-december-2023.pdf
18. Fundsmith 2022 short-form report - primary source for PayPal sale proceeds and Intuit/share-based compensation context. https://www.fundsmith.co.uk/media/y3ll0d4j/2022-short-form-report-for-the-twelve-months-ended-31-december-2022.pdf
19. Fundsmith 2015 short-form report - primary source for Domino's sale proceeds. https://www.fundsmith.co.uk/media/iqqjjf5o/2015-short-form-report-for-the-twelve-months-ended-31st-december-2015.pdf
20. Fundsmith 2011 short-form report - primary source for early portfolio weights, including Microsoft and Stryker. https://www.fundsmith.co.uk/media/vcjbyrln/short-form-report-for-period-ended-31st-dec-2011.pdf
21. Fundsmith factsheet/current holdings page - current source for ongoing top holdings and latest official factsheet target. https://www.fundsmith.co.uk/factsheet/
22. Fundsmith LLP Q1 2016 13F - SEC source for Microsoft, Philip Morris, Stryker and IDEXX U.S.-reportable position values. https://www.sec.gov/Archives/edgar/data/1569205/000138713116005089/0001387131-16-005089.txt
23. Fundsmith LLP Q4 2021 13F - SEC source for peak-era Microsoft, IDEXX, PayPal, Meta, Philip Morris and Stryker reported holding values. https://www.sec.gov/Archives/edgar/data/1569205/000186853722000005/0001868537-22-000005.txt
24. Fundsmith LLP Q3 2024 13F - SEC source for 2024 Microsoft/Meta/Stryker/Visa/Philip Morris reported values. https://www.sec.gov/Archives/edgar/data/1569205/000152002324000040/0001520023-24-000040.txt
25. Fundsmith LLP Q2 2025 13F - SEC source for 2025 Meta/Microsoft/Stryker/Philip Morris/IDEXX reported values. https://www.sec.gov/Archives/edgar/data/1569205/000180154725000008/0001801547-25-000008.txt
26. Fundsmith LLP Q1 2026 13F - latest opened SEC source for reported U.S. holdings and ongoing Microsoft/Meta/Stryker/Philip Morris/IDEXX values after trims. https://www.sec.gov/Archives/edgar/data/1569205/000156920526000005/0001569205-26-000005.txt
27. Fundsmith Q4 2013 13F info table - SEC source for early Domino's and Stryker U.S.-reportable values; CUSIP/ticker mapping caveat retained. https://www.sec.gov/Archives/edgar/data/1569205/000138713114000234/xslForm13F_X01/infotable.xml
28. Fundsmith IDEXX Schedule 13G, 2023 - SEC source for 4.448m IDEXX shares / 5.37% beneficial ownership. https://www.sec.gov/Archives/edgar/data/1569205/0001520023-23-000005.txt
29. SEC Form 13F FAQ - source for limitations of 13F as quarter-end holdings rather than full P&L/cost-basis evidence. https://www.sec.gov/rules-regulations/staff-guidance/division-investment-management-frequently-asked-questions/frequently-asked-questions-about-form-13f
30. SEC Form 13F data sets page - source for SEC caveat that extracted 13F data are as filed and not guaranteed by SEC. https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets
31. Morningstar downgrade, 2024 - independent critique of Fundsmith sell discipline, including Amazon/Adobe/PayPal/Estee Lauder examples. https://global.morningstar.com/en-gb/funds/morningstar-downgrades-fundsmith-equity-from-gold-to-silver
32. Guardian coverage of Morningstar downgrade, 2024 - accessible secondary corroboration of downgrade and sell-discipline critique. https://www.theguardian.com/business/2024/mar/28/stock-picker-terry-smith-fundsmith-equity-downgraded-by-ratings-firm-share-sales
33. Interactive Investor, 2026, Microsoft/Meta trims - current secondary source on Smith halving Microsoft and Meta exposure over AI capex concerns. https://www.ii.co.uk/analysis-commentary/why-terry-smith-halved-his-microsoft-exposure-ii538505
34. Trustnet, 2025, annual performance commentary - secondary corroboration for 2024 contributors/detractors and Smith's criticism framing. https://www.trustnet.com/news/13434476/terry-smith-on-how-he-will-smile-through-the-pain-of-underperformance
35. Portfolio Adviser, 2025, H1 purchases/exits/laggards - secondary source for 2025 attribution, Novo/Coloplast discussion and laggard context. https://portfolio-adviser.com/terry-smith-on-fundsmiths-first-half-purchases-exits-and-laggards/
36. AJ Bell, 2025, Denmark/Novo critique - secondary source for Novo/Coloplast drawdown and underperformance framing. https://www.ajbell.co.uk/group/news/something-rotten-state-denmark-haunts-fundsmith
37. Smithson 2025 report - primary source for excluding Smithson from Terry Smith's direct greatest-trades list. https://www.smithson.co.uk/media/laslz1yj/report-for-the-year-ended-31-december-2025.pdf
38. FEET final report - primary source for excluding/warning on Fundsmith Emerging Equities Trust. https://www.fundsmith.co.uk/media/i5qnbwzt/feet-final-report.pdf
39. Fundsmith Stewardship factsheet - primary source for excluding Stewardship/Sustainable as a greatest-trades candidate due to vehicle-level record and mandate differences. https://www.fundsmith.co.uk/fsf/factsheet/
40. Fundsmith Equity ETF site - primary source for excluding the U.S. ETF as too new and as a wrapper rather than a separate trade. https://www.fundsmithetf.us/
41. Morningstar review, 2026 - independent current check on underperformance, sell-discipline monitoring, key-person/internal-challenge risk, and stock-specific pain. https://global.morningstar.com/en-gb/funds/fundsmith-equity-fund-retains-appeal-long-term-investors

Task C caveats

• Fundsmith does not disclose trade-level cost basis, full entry/exit dates, realized stock-level gains, or stock-level IRRs; do not convert contribution data into P&L.
• Annual top-contributor attribution is performance contribution to Fundsmith Equity Fund, usually sourced to State Street in the annual letters.
• SEC 13F data are U.S.-reportable quarter-end snapshots, not full Fundsmith exposure, and exclude many non-U.S. ordinary shares.
• The IDEXX 2023 Schedule 13G/A reports 4.448m shares / 5.37% around year-end 2022 but also checks Item 5 to report Fundsmith had ceased to be a greater-than-5% owner as of the filing date; do not use it as proof of later above-5% ownership.
• Novo Nordisk and PayPal are included as mixed trades, not clean triumphs; future D-mistakes work should revisit them from the loss/sell-discipline side.
• Smithson, FEET, Stewardship/Sustainable, and the ETF are franchise/vehicle evidence, not direct Terry Smith greatest-trade candidates.

T0305 - F-key-writings sources (2026-07-03T17:44:05Z)

1. Fundsmith document archive - canonical index for Owner's Manual, annual letters, reports, and papers. https://www.fundsmith.co.uk/documents/
2. Fundsmith Equity Fund Owner's Manual 2025 - core client contract and process statement. https://www.fundsmith.co.uk/media/mv3abv1h/fef-owners-manual-a4-2025.pdf
3. Fundsmith Equity Fund Annual Letter to Shareholders 2025 - current underperformance discussion, index concentration, passive flows, dollar weakness. https://www.fundsmith.co.uk/media/4hcfd1pg/2025-fef-annual-letter-web.pdf
4. Fundsmith Equity Fund Annual Letter to Shareholders 2024 - three-step strategy and look-through quality scorecard. https://www.fundsmith.co.uk/media/pirmvyly/annual-letter-to-shareholders-2024.pdf
5. Fundsmith Equity Fund Annual Letter to Shareholders 2022 - technology classification, inflation, share-based compensation accounting. https://www.fundsmith.co.uk/media/bm0lyc22/annual-letter-to-shareholders-2022.pdf
6. Fundsmith Equity Fund Annual Letter to Shareholders 2021 - companies-not-countries and long-term ownership framing. https://www.fundsmith.co.uk/media/3wcngjie/2021-fef-annual-letter-to-shareholders-web.pdf
7. Fundsmith Equity Fund Annual Letter to Shareholders 2018 - inactivity and long holding-period discipline. https://www.fundsmith.co.uk/media/sulfjbdr/annual-letter-to-shareholders-2018.pdf
8. Fundsmith Equity Fund Annual Letter to Shareholders 2014 - macro humility and process discipline. https://www.fundsmith.co.uk/media/wiulqdhi/annual-letter-to-shareholders-2014.pdf
9. Accounting for Growth, 1996 edition catalog record - bibliographic metadata, access restriction, publication details. https://archive.org/details/accountingforgro0000smit_y4v0
10. Accounting for Growth, 1992 edition catalog record - original edition metadata. https://archive.org/details/accountingforgro0000smit
11. Harriman House: Investing for Growth (Second Edition), 2026 - publisher synopsis, ISBN, page count, 2020-2025 update note. https://harriman-house.com/authors/terry-smith/investing-for-growth-second-edition/9781804093733
12. Google Books: Investing for Growth, 2020 - bibliographic cross-check. https://books.google.com/books/about/Investing_for_Growth.html?id=JygEEAAAQBAJ
13. Terry Smith, "What I have learnt at Fundsmith in the past five years" - quality vs cheapness, reading accounts, sell discipline. https://www.fundsmith.co.uk/news/2015/2072-financial-times-terry-smith-what-i-have-learnt-at-fundsmith-in-the-past-five-years/
14. Terry Smith, "Ten golden rules of investment" - private-investor rule set and market-timing warning. https://www.fundsmith.co.uk/news/2013/2070-financial-times-ten-golden-rules-of-investment/
15. Terry Smith, "The unique advantage of equity investment" - retained earnings and high-return compounding. https://www.fundsmith.co.uk/news/2017/2073-financial-times-the-unique-advantage-of-equity-investment/
16. Terry Smith, "How investors ignored the warning signs at Tesco" - ROCE deterioration versus EPS growth. https://www.fundsmith.co.uk/news/2014/2050-financial-times-how-investors-ignored-the-warning-signs-at-tesco/
17. Terry Smith, "Why bother cooking the books if no one reads them?" - non-GAAP/core earnings critique and Accounting for Growth retrospective. https://www.fundsmith.co.uk/news/2015/2081-financial-times-why-bother-cooking-the-books-if-no-one-reads-them/
18. Terry Smith, "AstraZeneca is beginning to look a lot like Tesco" - accounting quality, recurring costs, and return-on-capital concerns. https://www.fundsmith.co.uk/news/2017/2038-financial-times-astrazeneca-is-beginning-to-look-like-tesco/
19. Terry Smith, "Why I never invest in bank shares" - negative screen against leverage-dependent returns. https://www.fundsmith.co.uk/news/2023/4933-financial-times-why-i-never-invest-in-bank-shares/
20. Terry Smith, "Two and Twenty" - fee drag and fund-manager incentive critique. https://www.fundsmith.co.uk/news/2010/2086-fund-management-fees-two-and-twenty/
21. Terry Smith, "Share Buybacks" - capital-allocation test for repurchases. https://www.fundsmith.co.uk/media/pnbnh5we/share-buybacks-pdf.pdf
22. Terry Smith, "Lessons from the Tour de France" - long-race behavior analogy. https://www.fundsmith.co.uk/media/qbyft33m/lessons-from-the-tour-de-france-pdf.pdf
23. Terry Smith, "Return Free Risk" - critique of risk/return cliches. https://www.fundsmith.co.uk/media/hafpybqk/return-free-risk-pdf.pdf
24. Terry Smith, "Banned Words" - management-language warning checklist. https://www.fundsmith.co.uk/media/uydhgdlx/banned-words-pdf.pdf
25. Fundsmith, "Unilever + GSK Consumer: A post mortem" - stewardship and capital-allocation case note. https://www.fundsmith.co.uk/media/iljh250j/fundsmith_unilever_and_gsk.pdf
26. Morningstar, "Fundsmith Equity Fund Retains Appeal for Long-Term Investors" - current third-party critique, process and performance context. https://global.morningstar.com/en-gb/funds/fundsmith-equity-fund-retains-appeal-long-term-investors
27. Morningstar, "Morningstar Downgrades Fundsmith Equity from Gold to Silver" - 2024 outside critique of sell discipline and valuation context. https://global.morningstar.com/en-gb/funds/morningstar-downgrades-fundsmith-equity-from-gold-to-silver
28. The Market/NZZ interview mirrored by Fundsmith - oral supplement on quality vs valuation; treated as secondary to written works. https://www.fundsmith.co.uk/news/2024/5553-the-market-nzz-valuation-is-not-as-important-as-quality/
29. Richer Wiser Happier podcast episode - biographical and temperament supplement; transcript/audio should be checked before exact quotation. https://www.theinvestorspodcast.com/richer-wiser-happier/billionaire-brit-w-terry-smith/

Research limitations: Accounting for Growth was verified from catalog metadata and Smith's later writings, not page-quoted, because the archive scan is access-restricted. The 2026 Investing for Growth second edition was verified from Harriman House metadata and publisher synopsis; chapter-level page verification remains open. Interviews were used only as secondary context unless mirrored in written Fundsmith materials.

T0306 - G-mental-models sources (2026-07-03T18:36:30Z)

1. Fundsmith Equity Fund Owner's Manual 2025 - primary source for the three-part doctrine, high-ROCE/cash-return criteria, intangible-franchise model, anti-leverage screen, benchmark independence, and investor temperament. https://www.fundsmith.co.uk/media/mv3abv1h/fef-owners-manual-a4-2025.pdf
2. Fundsmith Equity Fund Prospectus 2026 - primary legal/product source for UCITS spread rules, borrowing limit, no derivatives/hedging/securities-financing rules, investment powers, and open-ended vehicle constraints. https://www.fundsmith.co.uk/media/5gtnxzgh/fundsmith-equity-fund-prospectus-2026.pdf
3. Fundsmith Equity Fund factsheet, June 2026 - primary current snapshot for holdings count, cash, active share, liquidity, performance lag, fund size, and stated investment criteria. https://www.fundsmith.co.uk/media/b22dtyny/june.pdf
4. Fundsmith 2025 annual letter, dated January 2026 - primary source for 2025 scorecard metrics, FCF yield comparison, turnover, passive/index concentration critique, Microsoft/Meta/Novo/IDEXX commentary, and Brown-Forman/PepsiCo sell examples. https://www.fundsmith.co.uk/media/4hcfd1pg/2025-fef-annual-letter-web.pdf
5. Fundsmith 2024 annual letter, dated January 2025 - primary source for Nvidia/AI opportunity-cost framing, 2024 scorecard, AI capex return question, IDEXX holding rationale, and 2024 turnover. https://www.fundsmith.co.uk/media/pirmvyly/annual-letter-to-shareholders-2024.pdf
6. Fundsmith 2025 semiannual letter - primary source for Novo/Coloplast first-half underperformance framing and current sell-discipline stress. https://www.fundsmith.co.uk/media/bvgden5v/2025-fef-semi-annual-letter-to-shareholders.pdf
7. Fundsmith 2023 annual letter - primary source for Magnificent Seven concentration context, Microsoft and Novo examples, and quality-growth benchmark tension. https://www.fundsmith.co.uk/media/31plodnq/2023-fef-annual-letter-to-shareholders.pdf
8. Fundsmith 2022 annual letter - primary source for PayPal/Intuit concerns, share-based-compensation treatment, rising-rate drawdown context, and technology holding commentary. https://www.fundsmith.co.uk/media/bm0lyc22/annual-letter-to-shareholders-2022.pdf
9. Fundsmith 2017 annual letter - primary source for PayPal and Novo contribution history and early quality-compounder evidence. https://www.fundsmith.co.uk/media/ceadumtv/annual-letter-to-shareholders-2017.pdf
10. Fundsmith 2016 annual letter - primary source for Domino's regret, IDEXX/Stryker/Novo early evidence, and valuation-discipline trade-off. https://www.fundsmith.co.uk/media/wmul2sfh/2016-annual-letter-to-shareholders.pdf
11. Fundsmith 2015 annual letter - primary source for Domino's sale context and valuation-discipline evidence. https://www.fundsmith.co.uk/media/5jgdehk1/annual-letter-to-shareholders-2015.pdf
12. Fundsmith 2011 annual letter - primary source for early Domino's sale, Stryker/Philip Morris context, and founding-period portfolio evidence. https://www.fundsmith.co.uk/media/khugzwcd/annual-letter-to-shareholders-2011-pdf.pdf
13. Accounting for Growth, 1996 edition catalog record - bibliographic verification for Smith's accounting-forensics roots; access-restricted, not used for page quotations. https://archive.org/details/accountingforgro0000smit_y4v0
14. Accounting for Growth, 1992 edition catalog record - bibliographic verification for original edition provenance. https://archive.org/details/accountingforgro0000smit
15. Pan Macmillan Terry Smith author biography - publisher corroboration of Accounting for Growth career context and UBS Phillips & Drew dismissal. https://www.panmacmillan.com/authors/terry-smith/48467
16. Terry Smith, "Why bother cooking the books if no one reads them?" - primary first-person retrospective on accounting camouflage, adjusted profit, and why accounting skepticism remains central. https://www.fundsmith.co.uk/news/2015/2081-financial-times-why-bother-cooking-the-books-if-no-one-reads-them/
17. Terry Smith, Tesco essay, 2014 - primary worked example for EPS versus ROCE/cash/debt/definition-change forensic checklist. https://www.fundsmith.co.uk/news/2014/2050-financial-times-how-investors-ignored-the-warning-signs-at-tesco/
18. Terry Smith, AstraZeneca essay, 2017 - primary worked example for "core" earnings, recurring costs, intangible amortization, and return-on-capital deterioration. https://www.fundsmith.co.uk/news/2017/2038-financial-times-astrazeneca-is-beginning-to-look-like-tesco/
19. Terry Smith, "Why I never invest in bank shares," 2023 - primary source for leverage-dependent business exclusion and bank risk model. https://www.fundsmith.co.uk/news/2023/4933-financial-times-why-i-never-invest-in-bank-shares/
20. Terry Smith, bank shares essay, 2014 - primary earlier source for anti-bank/leverage logic. https://www.fundsmith.co.uk/news/2014/2083-financial-times-why-i-don-t-own-bank-shares/
21. Terry Smith, "The unique advantage of equity investment" - primary source for retained earnings, reinvestment runway, and high-return equity compounding. https://www.fundsmith.co.uk/news/2017/2073-financial-times-the-unique-advantage-of-equity-investment/
22. Terry Smith, "Share Buybacks" - primary source for buyback capital-allocation checklist and EPS-optics caution. https://www.fundsmith.co.uk/media/pnbnh5we/share-buybacks-pdf.pdf
23. Terry Smith/Fundsmith, "Unilever + GSK Consumer: A post mortem" - primary stewardship and capital-allocation case note. https://www.fundsmith.co.uk/media/iljh250j/fundsmith_unilever_and_gsk.pdf
24. Terry Smith, "Banned Words" - primary source for management-language warning model. https://www.fundsmith.co.uk/media/uydhgdlx/banned-words-pdf.pdf
25. Terry Smith, "Return Free Risk" - primary source for quality-risk model and rejection of simplistic risk-return cliches. https://www.fundsmith.co.uk/media/hafpybqk/return-free-risk-pdf.pdf
26. Terry Smith, "Two and Twenty" - primary source for fees and activity as compounding drags. https://www.fundsmith.co.uk/news/2010/2086-fund-management-fees-two-and-twenty/
27. Fundsmith fees note, 2010 - primary supplement on fee drag and product alignment. https://www.fundsmith.co.uk/news/2010/2103-fundsmith-fees/
28. SEC Fundsmith LLP 13F Q1 2026 information table - official latest U.S.-reportable holdings snapshot used only for position-size context and trim evidence. https://www.sec.gov/Archives/edgar/data/1569205/000156920526000005/xslForm13F_X02/FLLPq12026.xml
29. SEC Fundsmith LLP 13F Q4 2021 information table - official U.S.-reportable peak-era snapshot for Microsoft/Meta/IDEXX/PayPal/Stryker/Philip Morris context. https://www.sec.gov/Archives/edgar/data/1569205/000186853722000005/xslForm13F_X01/FLLP_2021q4.xml
30. SEC Form 13F FAQ - source for limitations of 13F as quarter-end long-position snapshots without cost basis, P&L, cash, or full global exposure. https://www.sec.gov/rules-regulations/staff-guidance/division-investment-management-frequently-asked-questions/frequently-asked-questions-about-form-13f
31. Interactive Investor, 2026, Microsoft/Meta trims - secondary source for Smith/Fundsmith AI-capex rationale behind roughly halving Microsoft and Meta exposure. https://www.ii.co.uk/analysis-commentary/why-terry-smith-halved-his-microsoft-exposure-ii538505
32. Morningstar downgrade, 2024 - independent critique of sell discipline, early/late exits, and valuation uncertainty; key failure-mode source. https://global.morningstar.com/en-gb/funds/morningstar-downgrades-fundsmith-equity-from-gold-to-silver
33. Morningstar review, 2026 - current independent assessment retaining appeal but flagging underperformance, stock-specific issues, narrow-market leadership, and key-person/internal-challenge risk. https://global.morningstar.com/en-gb/funds/fundsmith-equity-fund-retains-appeal-long-term-investors
34. Fundsmith-hosted Morningstar managed investment report, 2026 - accessible version of the current Morningstar review and risk notes. https://www.fundsmith.co.uk/media/jbsni1u0/morningstar-managed-investment-report-2026.pdf
35. Guardian coverage of Morningstar downgrade, 2024 - accessible secondary corroboration of downgrade and sell-discipline critique. https://www.theguardian.com/business/2024/mar/28/stock-picker-terry-smith-fundsmith-equity-downgraded-by-ratings-firm-share-sales
36. AJ Bell, Fundsmith underperforms fifth calendar year in a row, 2026 - secondary critique of Novo/Coloplast concentration and recent relative performance. https://www.ajbell.co.uk/group/news/fundsmith-underperforms-fifth-calendar-year-row
37. Trustnet Smithson interview, 2023 - secondary source for Smithson managers' admission that turnover/transaction costs contributed to holding some stocks too long; used as Fundsmith-franchise evidence, not direct flagship evidence. https://www.trustnet.com/news/13394301/smithson-turnover-and-transaction-costs-factored-into-us-keeping-stocks-we-probably-should-have-sold
38. Trustnet FEET liquidation article, 2022 - secondary source for FEET performance shortfall and stated liquidation rationale. https://www.trustnet.com/news/13328539/fundsmith-liquidates-emerging-equities-trust-after-poor-performance
39. Fundsmith Emerging Equities Trust final report, 2025 - primary liquidation source for members' voluntary liquidation, distribution amount, and tax/settlement wind-down friction. https://www.fundsmith.co.uk/media/i5qnbwzt/feet-final-report.pdf
40. Companies House FEET insolvency record - official source confirming members' voluntary liquidation status rather than creditor insolvency. https://find-and-update.company-information.service.gov.uk/company/08756681/insolvency
41. Smithson Investment Trust 2025 report - primary source for small/mid-cap vehicle performance, discount, and reconstruction rationale context. https://www.smithson.co.uk/media/laslz1yj/report-for-the-year-ended-31-december-2025.pdf
42. Smithson restructure proposal - primary source for proposed OEIC reconstruction and persistent discount context. https://www.smithson.co.uk/restructure-proposal/
43. AJ Bell Smithson restructuring analysis, 2025 - secondary critique of vehicle-transferability and Saba/governance pressure context. https://www.ajbell.co.uk/group/news/terry-smith-sides-activist-investor-saba-major-changes-proposed-smithson-investment-trust

Task G caveats: Tasks D and E were still freshly claimed and unavailable, so this mental-models file was built from completed A/B/C files plus fresh Task G checks. Most doctrine evidence is first-party Smith/Fundsmith material, which is primary but self-framing. Smithson and FEET are Fundsmith-franchise evidence and should not be treated as direct flagship trade evidence. 13F filings are incomplete U.S. long-position snapshots, not full portfolio, cost-basis, or P&L evidence. Accounting for Growth remains bibliography-verified but not page-verified.

T0307 - H-synthesis sources (2026-07-03T19:43:21Z)

1. Fundsmith Equity Fund factsheet page - current price/factsheet hub and latest share-class snapshot. https://www.fundsmith.co.uk/factsheet/
2. Fundsmith Equity Fund factsheet, June 2026 - primary current source for fund size, holdings count, OCF, cash, active share, liquidity, geography, top ten holdings, and performance through 30 June 2026. https://www.fundsmith.co.uk/media/b22dtyny/june.pdf
3. Fundsmith 2025 annual letter, dated January 2026 - primary source for 2025 performance, benchmark lag explanation, turnover, contributors/detractors, sells, and new buys. https://www.fundsmith.co.uk/media/4hcfd1pg/2025-fef-annual-letter-web.pdf
4. Fundsmith 2024 annual letter, dated January 2025 - primary source for AI/index-concentration framing, 2024 scorecard, and recent benchmark-lag context. https://www.fundsmith.co.uk/media/pirmvyly/annual-letter-to-shareholders-2024.pdf
5. Fundsmith 2022 annual letter - primary source for rising-rate drawdown context, PayPal/Intuit discussion, and share-based-compensation/accounting arguments. https://www.fundsmith.co.uk/media/bm0lyc22/annual-letter-to-shareholders-2022.pdf
6. Fundsmith Equity Fund Owner's Manual 2025 - primary doctrine source for the three-step process, quality criteria, buy-and-hold discipline, benchmark independence, and anti-leverage rules. https://www.fundsmith.co.uk/media/mv3abv1h/fef-owners-manual-a4-2025.pdf
7. Fundsmith Equity Fund Prospectus 2026 - legal/product source for the UK OEIC structure, ACD, concentration norms, UCITS powers, no-derivatives/no-hedging policy, and liquidity constraints. https://www.fundsmith.co.uk/media/5gtnxzgh/fundsmith-equity-fund-prospectus-2026.pdf
8. SEC Fundsmith LLP Form 13F primary document, Q1 2026 - official latest filing metadata, filing date, reporting date, manager identity, and aggregate reported value. https://www.sec.gov/Archives/edgar/data/1569205/000156920526000005/xslForm13F_X02/primary_doc.xml
9. SEC Fundsmith LLP Form 13F information table, Q1 2026 - official latest U.S.-reportable holdings table used for current U.S. exposure context and 13F trend checks. https://www.sec.gov/Archives/edgar/data/1569205/000156920526000005/xslForm13F_X02/FLLPq12026.xml
10. SEC Form 13F FAQ - source for 13F limitations as quarter-end long-position snapshots without full global portfolio, cash, cost basis, or P&L evidence. https://www.sec.gov/rules-regulations/staff-guidance/division-investment-management-frequently-asked-questions/frequently-asked-questions-about-form-13f
11. Morningstar, "Fundsmith Equity Fund Retains Appeal for Long-Term Investors," 3 June 2026 - current independent review retaining Silver while flagging recent underperformance, narrow-market leadership, sell discipline, and key-person/internal-challenge risks. https://global.morningstar.com/en-gb/funds/fundsmith-equity-fund-retains-appeal-long-term-investors
12. Morningstar, "Morningstar Downgrades Fundsmith Equity from Gold to Silver," 27 March 2024 - independent critique of sell discipline, early/late sales, and valuation uncertainty. https://global.morningstar.com/en-gb/funds/morningstar-downgrades-fundsmith-equity-from-gold-to-silver
13. The Guardian, "Star stock-picker Terry Smith's fund downgraded by ratings firm," 28 March 2024 - accessible secondary corroboration of the Morningstar downgrade and sell-discipline criticism. https://www.theguardian.com/business/2024/mar/28/stock-picker-terry-smith-fundsmith-equity-downgraded-by-ratings-firm-share-sales
14. Smithson Investment Trust annual report 2025 - primary source for small/mid-cap vehicle performance, discount, reconstruction rationale, and Fundsmith-franchise transferability evidence. https://www.smithson.co.uk/media/laslz1yj/report-for-the-year-ended-31-december-2025.pdf
15. Fundsmith Emerging Equities Trust final report - primary source for members' voluntary liquidation mechanics, distributions, and wind-down evidence. https://www.fundsmith.co.uk/media/i5qnbwzt/feet-final-report.pdf
16. Trustnet, "Fundsmith liquidates Emerging Equities Trust after poor performance" - secondary source for FEET performance shortfall and stated liquidation rationale. https://www.trustnet.com/news/13328539/fundsmith-liquidates-emerging-equities-trust-after-poor-performance
17. AJ Bell, "Terry Smith sides with activist investor Saba..." - secondary critique of Smithson's proposed OEIC restructuring and vehicle-fit issues. https://www.ajbell.co.uk/group/news/terry-smith-sides-activist-investor-saba-major-changes-proposed-smithson-investment-trust
18. Interactive Investor, "Why Terry Smith halved his Microsoft exposure" - secondary source for 2026 Microsoft/Meta trim framing and AI-capex concerns. https://www.ii.co.uk/analysis-commentary/why-terry-smith-halved-his-microsoft-exposure-ii538505
19. UBS market concentration commentary - independent market-context source for S&P 500 top-ten concentration near 40%. https://www.ubs.com/global/en/wealthmanagement/insights/marketnews/article.3471267.html
20. Financial News, "Terry Smith's flagship equity fund suffers record outflows of £3.3bn" - secondary outflow reporting; partly paywalled, used only for headline/lead-level corroboration. https://www.fnlondon.com/articles/terry-smiths-flagship-equity-fund-suffers-record-outflows-of-3-3bn-65e2bf45
21. Financial News, "Fundsmith heads towards record year of outflows as investors pull more than £5bn" - secondary outflow reporting; partly paywalled, used only for headline/lead-level corroboration. https://www.fnlondon.com/articles/fundsmith-heads-towards-record-year-of-outflows-as-investors-pull-more-than-5bn-4665fb02
22. Financial News, "Investors pull another £1.7bn from Terry Smith's flagship fund" - secondary Q1 2026 outflow reporting; partly paywalled, used only for headline/lead-level corroboration. https://www.fnlondon.com/articles/investors-pull-another-1-7bn-from-terry-smiths-flagship-fund-66a10011
23. Fundsmith Equity Fund factsheet, December 2021 - primary peak-era snapshot for since-inception performance and flagship fund size at 31 December 2021. https://www.fundsmith.co.uk/media/3cubp5wr/december.pdf
24. Fundsmith global site - current firmwide AUM context shown on the global homepage; date/scope differs from flagship factsheet. https://www.fundsmith.com/
25. FCA skilled-person reviews overview - generic official source for Section 166 review mechanics; does not confirm Fundsmith-specific facts. https://www.fca.org.uk/about/how-we-regulate/supervision/skilled-persons-reviews
26. Portfolio Adviser, "Fundsmith handed clean sheet after Section 166 review" - secondary report on a claimed clean-sheet result; used with caution because it is not an FCA final notice. https://portfolio-adviser.com/fundsmith-handed-clean-sheet-after-section-166-review/

Task H caveats: Tasks D and E remained claimed when this synthesis was written, so the synthesis relies on completed A/B/C/F/G outputs plus five fresh research lanes and current factsheet, 13F, Morningstar, vehicle, and criticism checks. 13F evidence is incomplete U.S.-reportable long-position data, not full global portfolio or P&L. FEET final-report evidence supports liquidation mechanics, while poor-performance rationale comes from secondary reporting. Financial News outflow items were partly paywalled and used only where headline/lead text was visible. The current Fundsmith factsheet, year-end annual letter, global homepage, and 13F filings have different dates and scopes; differences in holdings and assets are treated as date/scope effects, not contradictions.

T0303 - D-mistakes sources (2026-07-03T20:24:28Z)

1. Fundsmith Equity Fund factsheet, June 2026 - primary source for T Acc performance rows through 30 June 2026, inception-to-date and annualised returns, fund size, holdings count, cash, and benchmark/comparator caveat. https://www.fundsmith.co.uk/media/b22dtyny/june.pdf
2. Fundsmith Equity Fund factsheet, December 2021 - primary high-water reference for pre-drawdown flagship size and since-inception record before the 2022-2026 relative-performance slump. https://www.fundsmith.co.uk/media/3cubp5wr/december.pdf
3. Fundsmith 2025 annual letter, dated January 2026 - primary source for 2025 underperformance, index concentration/passive-flow explanation, Novo/Coloplast/Brown-Forman/PepsiCo discussion, and sell examples. https://www.fundsmith.co.uk/media/4hcfd1pg/2025-fef-annual-letter-web.pdf
4. Fundsmith 2025 semiannual letter - primary source for first-half 2025 performance, Novo/Coloplast pressure, and current sell-discipline stress before the full-year letter. https://www.fundsmith.co.uk/media/bvgden5v/2025-fef-semi-annual-letter-to-shareholders.pdf
5. Fundsmith 2024 annual letter, dated January 2025 - primary source for AI/Nvidia omission framing, 2024 underperformance, IDEXX/Novo commentary, and quality-scorecard context. https://www.fundsmith.co.uk/media/pirmvyly/annual-letter-to-shareholders-2024.pdf
6. Fundsmith 2023 annual letter - primary source for Estee Lauder detractor evidence, Magnificent Seven benchmark concentration, and Microsoft/Novo quality-growth tension. https://www.fundsmith.co.uk/media/31plodnq/2023-fef-annual-letter-to-shareholders.pdf
7. Fundsmith 2022 annual letter - primary source for the 2022 drawdown, PayPal/Intuit and rising-rate explanations, technology-classification framing, and 2022 sales. https://www.fundsmith.co.uk/media/bm0lyc22/annual-letter-to-shareholders-2022.pdf
8. Fundsmith 2022 semiannual letter - primary source for first-half PayPal detractor evidence and Smith's early 2022 commentary on self-inflicted wounds. https://www.fundsmith.co.uk/media/jhnc4xoi/2022-fef-semi-annual-letter.pdf
9. Fundsmith 2022 short-form report - primary source for PayPal sale proceeds and report-level evidence around 2022 portfolio changes. https://www.fundsmith.co.uk/media/y3ll0d4j/2022-short-form-report-for-the-twelve-months-ended-31-december-2022.pdf
10. Morningstar downgrade, March 2024 - independent critique of sell discipline, specifically PayPal/Estee Lauder late exits and Amazon/Adobe early exits. https://global.morningstar.com/en-gb/funds/morningstar-downgrades-fundsmith-equity-from-gold-to-silver
11. Fundsmith-hosted Morningstar managed investment report, 2024 - accessible report version supporting the sell-discipline critique and process-rating downgrade context. https://www.fundsmith.eu/media/mgjh0rkx/morningstar-report-fundsmith-equity-fund-sicav-march-2024.pdf
12. Morningstar review, June 2026 - current independent view retaining appeal while flagging recent underperformance, narrow-market leadership, sell discipline, key-person risk, and internal challenge. https://global.morningstar.com/en-gb/funds/fundsmith-equity-fund-retains-appeal-long-term-investors
13. Guardian coverage of Morningstar downgrade, March 2024 - accessible secondary corroboration of downgrade, sell-discipline concerns, outflows, profits, and Smith pay context. https://www.theguardian.com/business/2024/mar/28/stock-picker-terry-smith-fundsmith-equity-downgraded-by-ratings-firm-share-sales
14. Portfolio Adviser PayPal article, 2023 - secondary source for Smith's criticism of PayPal management and operational momentum after the 2022 exit. https://portfolio-adviser.com/terry-smith-takes-aim-at-paypal-after-fundsmiths-poor-performance/
15. Portfolio Adviser first-half 2025 article - secondary source for Novo/Coloplast laggard context and 2025 Fundsmith purchase/exit discussion. https://portfolio-adviser.com/terry-smith-on-fundsmiths-first-half-purchases-exits-and-laggards/
16. AJ Bell Denmark/Fundsmith article, 2025 - secondary source for Novo/Coloplast concentration and Danish quality-stock drawdown framing. https://www.ajbell.co.uk/group/news/something-rotten-state-denmark-haunts-fundsmith
17. Estee Lauder FY2023 results - company source corroborating the operating backdrop for Fundsmith's Estee Lauder loss case, including sales weakness and travel-retail/Hainan/Korea pressure. https://www.elcompanies.com/en/news-and-media/newsroom/press-releases/2023/08-18-2023-114520984
18. Novo Nordisk 2025 annual report - company source for compounded semaglutide/legal-regulatory and commercial-execution context behind the Novo mistake discussion. https://annualreport.novonordisk.com/2025/strategic-aspirations/commercial-execution.html
19. Coloplast CEO announcement, 2025 - company source for CEO Kristian Villumsen stepping down, supporting Fundsmith's management-quality discussion. https://www.coloplast.com/news-and-media/press-releases/2025/Coloplast-CEO-Kristian-Villumsen-steps-down/
20. Brown-Forman FY2025 results - company source supporting the weakening consumer/alcohol backdrop behind Fundsmith's Brown-Forman sale. https://www.brown-forman.com/article/brown-forman-reports-fiscal-2025-results-june-5-2025
21. PepsiCo FY2025 results - company source supporting North American foods volume/profit pressure behind Fundsmith's PepsiCo sale thesis. https://investors.pepsico.com/docs/pepsico-5v9wci20/media/Files/investors/q4-2025-earnings-release.pdf
22. Diageo FY2024 results - company source for Latin America/Caribbean weakness and inventory actions used in the changing consumer-defensive thesis discussion. https://www.diageo.com/en/news-and-media/press-releases/2024/2024-preliminary-results-year-ended-30-june-2024
23. Interactive Investor Microsoft/Meta trims, 2026 - secondary source for AI-capex re-underwriting and roughly halved Microsoft/Meta exposure. https://www.ii.co.uk/analysis-commentary/why-terry-smith-halved-his-microsoft-exposure-ii538505
24. FEET prospectus, 2014 - primary launch/source document for Fundsmith Emerging Equities Trust and Smith's original role/brand attribution. https://ftalphaville-cdn.ft.com/wp-content/uploads/2014/06/feet.pdf
25. FEET 2022 half-year report - primary source for later FEET investment-manager review attribution and wind-up-period role caveats. https://data.fca.org.uk/artefacts/NSM/Portal/NI-000057469/NI-000057469.pdf
26. Fundsmith Emerging Equities Trust final report, 2025 - primary liquidation source for members' voluntary liquidation, total distributions, final NAV comparison, and wind-down mechanics. https://www.fundsmith.co.uk/media/i5qnbwzt/feet-final-report.pdf
27. Companies House FEET insolvency record - official source confirming the FEET process as members' voluntary liquidation rather than creditor insolvency. https://find-and-update.company-information.service.gov.uk/company/08756681/insolvency
28. Trustnet FEET liquidation article, 2022 - secondary source for poor-performance rationale and Smith's fee/capital comments around the emerging-equities trust wind-up. https://www.trustnet.com/news/13328539/fundsmith-liquidates-emerging-equities-trust-after-poor-performance
29. Smithson restructuring circular, 2026 - primary source for persistent discount, buybacks, NAV/index return comparison, lead portfolio manager attribution, and proposed OEIC rollover. https://www.smithson.co.uk/media/xoufpghc/circular.pdf
30. Smithson Investment Trust 2025 annual report - primary source for small/mid-cap vehicle performance, discount, buybacks, and Fundsmith-franchise transferability evidence. https://www.smithson.co.uk/media/laslz1yj/report-for-the-year-ended-31-december-2025.pdf
31. Smithson restructure proposal page - primary/current company source for the OEIC reconstruction proposal and shareholder options. https://www.smithson.co.uk/restructure-proposal/
32. AJ Bell Smithson restructuring analysis, 2025 - secondary critique of Smithson vehicle-transferability and Saba/governance pressure context. https://www.ajbell.co.uk/group/news/terry-smith-sides-activist-investor-saba-major-changes-proposed-smithson-investment-trust
33. Trustnet Smithson interview, 2023 - secondary source for Smithson managers' admission that turnover/transaction costs contributed to holding some stocks too long. https://www.trustnet.com/news/13394301/smithson-turnover-and-transaction-costs-factored-into-us-keeping-stocks-we-probably-should-have-sold
34. Fundsmith Unilever + GSK Consumer post mortem, 2022 - primary Fundsmith stewardship source for public critique of Unilever's failed GSK Consumer bid and capital-allocation process. https://www.fundsmith.co.uk/media/iljh250j/fundsmith_unilever_and_gsk.pdf
35. Reuters/MarketScreener Unilever report, 2022 - secondary report on Smith urging Unilever to focus on operating performance after the GSK Consumer bid. https://uk.marketscreener.com/quote/stock/GSK-PLC-9590199/news/Shareholder-Terry-Smith-labels-Unilever-s-GSK-bid-near-death-experience-37600363/
36. Portfolio Adviser May 2022 Section 166 report - secondary source for the reported FCA-mandated skilled-person review; use with official FCA guidance because no Fundsmith final notice was found. https://portfolio-adviser.com/fundsmith-to-undergo-fca-mandated-review/
37. Portfolio Adviser July 2022 Section 166 follow-up - secondary source reporting recommendations but no further required action after the review. https://portfolio-adviser.com/fundsmith-handed-clean-sheet-after-section-166-review/
38. FCA skilled-person reviews overview - official source for what Section 166 reviews are and why they are supervisory context rather than proof of enforcement by themselves. https://www.fca.org.uk/about/how-we-regulate/supervision/skilled-persons-reviews
39. Financial News 2024 flagship outflows article - secondary/paywalled source for outflow context; use headline/lead-level claims only unless independently cross-checked. https://www.fnlondon.com/articles/terry-smiths-flagship-equity-fund-suffers-record-outflows-of-3-3bn-65e2bf45
40. Financial News 2025 outflows article - secondary/paywalled source for continuing outflow context; use cautiously and triangulate with official accounts/fund-flow data. https://www.fnlondon.com/articles/fundsmith-heads-towards-record-year-of-outflows-as-investors-pull-more-than-5bn-4665fb02

Task D caveats: Fundsmith does not publish a full trade ledger, stock-level cost basis, realized P&L, or internal investment memos, so stock-level mistake sizing relies on annual contribution tables, sale disclosures, 13F snapshots where relevant, company reports, and independent criticism. Several outflow items are partly paywalled and should be treated as secondary lead-level evidence only. Smithson and FEET are Fundsmith-franchise/oversight evidence, not direct flagship Terry Smith portfolio-manager trade evidence. The Section 166 material is supervisory/reputational context, not a public enforcement finding in the reviewed sources.

T0304 - E-own-words sources (2026-07-03T23:29:57Z)

1. Fundsmith documents hub - canonical index for Owner's Manual, annual/semiannual letters, reports, and articles. https://www.fundsmith.co.uk/documents/
2. Fundsmith Equity Fund Owner's Manual 2025 - compact primary doctrine and quote source for process, investor behavior, fees, and benchmarks. https://www.fundsmith.co.uk/media/mv3abv1h/fef-owners-manual-a4-2025.pdf
3. Fundsmith TV / Annual Shareholders' Meeting 2026 - latest official video/Q&A; use timestamped quotes only. https://www.fundsmith.co.uk/tv/
4. 2025 annual letter - current underperformance, passive/index concentration, AI-capex skepticism, currency, and sell examples. https://www.fundsmith.co.uk/media/4hcfd1pg/2025-fef-annual-letter-web.pdf
5. 2025 semiannual letter - midyear discussion of Novo/Coloplast pressure and current process stress. https://www.fundsmith.co.uk/media/bvgden5v/2025-fef-semi-annual-letter-to-shareholders.pdf
6. 2024 annual letter - AI/Nvidia omission, quality scorecard, valuation discipline, and benchmark-lag framing. https://www.fundsmith.co.uk/media/pirmvyly/fundsmith-annual-letter-to-shareholders-2024.pdf
7. 2024 semiannual letter - narrow-market concentration and Nvidia/mega-cap context. https://www.fundsmith.co.uk/media/uznnt5w2/2024-fef-semi-annual-letter-to-shareholders.pdf
8. 2023 annual letter - Magnificent Seven concentration, Microsoft/Novo commentary, and long-term owner communication. https://www.fundsmith.co.uk/media/31plodnq/2023-fef-annual-letter-to-shareholders.pdf
9. 2023 semiannual letter - valuation, interest-rate, and portfolio-change commentary. https://www.fundsmith.co.uk/media/cygbfqd0/fef-2023-semi-annual-letter-web.pdf
10. 2022 annual letter - drawdown, rising rates, PayPal/Intuit, and accounting/share-based-compensation arguments. https://www.fundsmith.co.uk/media/bm0lyc22/annual-letter-to-shareholders-2022.pdf
11. 2022 semiannual letter - first-half drawdown and mistake framing. https://www.fundsmith.co.uk/media/jhnc4xoi/2022-fef-semi-annual-letter.pdf
12. 2021 annual letter - companies-not-countries, global exposure, and long-term ownership framing. https://www.fundsmith.co.uk/media/3wcngjie/2021-fef-annual-letter-to-shareholders-web.pdf
13. 2021 semiannual letter - quality/recovery-stock argument and media/outflow response. https://www.fundsmith.co.uk/media/4swb2rkk/semi-annual-letter-to-shareholders-2021.pdf
14. 2020 annual letter - pandemic-year resilience, fund comparisons, and quality-growth defense. https://www.fundsmith.co.uk/media/deujnq00/annual-letter-to-shareholders-2020.pdf
15. March 2020 letter - crisis-era discipline and uncertainty commentary. https://www.fundsmith.co.uk/media/qqglo3t4/2020-3-fef-letter-to-shareholders.pdf
16. 2019 annual letter - turnover, costs, repeat transactions, and long-term compounding themes. https://www.fundsmith.co.uk/media/hoeistqg/annual-letter-to-shareholders-2019.pdf
17. 2018 annual letter - inactivity/do-nothing discipline and investor-behavior material. https://www.fundsmith.co.uk/media/sulfjbdr/annual-letter-to-shareholders-2018.pdf
18. 2017 annual letter - quality growth, portfolio changes, and benchmark commentary. https://www.fundsmith.co.uk/media/ceadumtv/annual-letter-to-shareholders-2017.pdf
19. 2016 annual letter - valuation, high-quality businesses, and do-nothing framing. https://www.fundsmith.co.uk/media/wmul2sfh/2016-annual-letter-to-shareholders.pdf
20. 2015 annual letter - five-year lessons, Domino's, and market-timing language. https://www.fundsmith.co.uk/media/5jgdehk1/annual-letter-to-shareholders-2015.pdf
21. 2014 annual letter - macro humility, stock-selection process, and portfolio discipline. https://www.fundsmith.co.uk/media/wiulqdhi/annual-letter-to-shareholders-2014.pdf
22. 2013 annual letter - early process commentary, portfolio turnover, and investor expectations. https://www.fundsmith.co.uk/media/r42lzm0b/annual-letter-to-shareholders-2013-pdf.pdf
23. 2012 annual letter - outperformance-period warning, bank rejection, and Domino's mistake reversal. https://www.fundsmith.co.uk/media/h2qekhgk/annual-letter-to-shareholders-2012-pdf.pdf
24. 2011 annual letter - early post-launch owner communication and low-turnover framing. https://www.fundsmith.co.uk/media/khugzwcd/annual-letter-to-shareholders-2011-pdf.pdf
25. 2010 annual letter - launch-era manifesto and earliest fund-owner language. https://www.fundsmith.co.uk/media/2iiacacc/annual-letter-to-shareholders-2010-pdf.pdf
26. "Ten golden rules of investment" - private-investor rules; good source for short, quote-ready maxims. https://www.fundsmith.co.uk/news/2013/2070-financial-times-ten-golden-rules-of-investment/
27. "What I have learnt at Fundsmith in the past five years" - concentrated first-person philosophy, sell discipline, facts/accounts, and Domino's. https://www.fundsmith.co.uk/news/2015/2072-financial-times-terry-smith-what-i-have-learnt-at-fundsmith-in-the-past-five-years/
28. "Why bother cooking the books if no one reads them?" - Accounting for Growth retrospective and accounting-skepticism quotes. https://www.fundsmith.co.uk/news/2015/2081-financial-times-why-bother-cooking-the-books-if-no-one-reads-them/
29. "Why I never invest in bank shares" - direct anti-bank/leverage rationale; Fundsmith-hosted FT-origin article. https://www.fundsmith.co.uk/news/2023/4933-financial-times-why-i-never-invest-in-bank-shares/
30. "There are only two types of investors" - market-timing source. https://www.fundsmith.co.uk/news/2020/2074-financial-times-there-are-only-two-types-of-investors/
31. "There won't be another Buffett..." - Buffett/Berkshire advantages and equity-income critique. https://www.fundsmith.co.uk/news/2025/6157-financial-times-there-wont-be-another-buffett-because-no-one-will-have-his-advantages/
32. "The unique advantage of equity investment" - retained earnings and compounding argument. https://www.fundsmith.co.uk/news/2017/2073-financial-times-the-unique-advantage-of-equity-investment/
33. "Return Free Risk" - Smith's risk-return critique. https://www.fundsmith.co.uk/media/hafpybqk/return-free-risk-pdf.pdf
34. "Banned Words" - management-language red flags and accounting skepticism. https://www.fundsmith.co.uk/media/uydhgdlx/banned-words-pdf.pdf
35. "Share Buybacks" - capital-allocation framework; PDF is the stronger canonical source. https://www.fundsmith.co.uk/media/pnbnh5we/share-buybacks-pdf.pdf
36. Richer, Wiser, Happier interview transcript, 2025 - long-form life/process interview; transcript is AI-generated, so verify wording before exact quotes. https://www.theinvestorspodcast.com/richer-wiser-happier/billionaire-brit-w-terry-smith/
37. Behind the Balance Sheet, "The Pugilist," 2026 - current interview transcript on underperformance, ambition, process, AI, and portfolio thinking; visibly noisy, so audio-check exact quotes. https://behindthebalancesheet.com/podcasts-singles/55-the-pugilist/
38. The Market/NZZ interview, 2024 - near-primary edited interview on quality vs. valuation, Novo, Magnificent Seven, and excluded sectors. https://www.fundsmith.co.uk/news/2024/5553-5553-the-market-nzz-valuation-is-not-as-important-as-quality/
39. Interactive Investor 100th episode interview, 2024 - near-primary full interview transcript on Diageo, Nvidia omission, Magnificent Seven, and equity-income view. https://www.ii.co.uk/analysis-commentary/100th-episode-special-terry-smith-interview-ii532854

Task E caveats: Prefer Fundsmith PDFs/articles for exact quotes. Treat The Market/NZZ and Interactive Investor as near-primary edited/direct interviews. Use Money Maze as an audio/video lead only; no usable transcript was verified. TIP/Richer Wiser Happier and Behind the Balance Sheet transcripts need audio checks before exact quotation. Treat Fundsmith TV as the primary AGM source and Steady Compounding as a secondary transcript companion. The Tesco snippet used in the quote file appears as headline/deck wording on a Fundsmith-hosted FT-origin article, so future page-level work should replace it if a stronger body-text quote is desired.